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SUMMARY
Since the first antiviral drug, idoxuridine, was approved in 1963,
90 antiviral drugs categorized into 13 functional groups have been
formally approved for the treatment of the following 9 human
infectious diseases: (i) HIV infections (protease inhibitors, inte-
grase inhibitors, entry inhibitors, nucleoside reverse transcriptase
inhibitors, nonnucleoside reverse transcriptase inhibitors, and
acyclic nucleoside phosphonate analogues), (ii) hepatitis B virus
(HBV) infections (lamivudine, interferons, nucleoside analogues,
and acyclic nucleoside phosphonate analogues), (iii) hepatitis C
virus (HCV) infections (ribavirin, interferons, NS3/4A protease
inhibitors, NS5A inhibitors, and NS5B polymerase inhibitors),
(iv) herpesvirus infections (5-substituted 2=-deoxyuridine ana-
logues, entry inhibitors, nucleoside analogues, pyrophosphate an-
alogues, and acyclic guanosine analogues), (v) influenza virus in-
fections (ribavirin, matrix 2 protein inhibitors, RNA polymerase
inhibitors, and neuraminidase inhibitors), (vi) human cytomega-
lovirus infections (acyclic guanosine analogues, acyclic nucleoside
phosphonate analogues, pyrophosphate analogues, and oligonu-
cleotides), (vii) varicella-zoster virus infections (acyclic guanosine
analogues, nucleoside analogues, 5-substituted 2=-deoxyuridine
analogues, and antibodies), (viii) respiratory syncytial virus infec-
tions (ribavirin and antibodies), and (ix) external anogenital warts
caused by human papillomavirus infections (imiquimod, sinecat-
echins, and podofilox). Here, we present for the first time a com-
prehensive overview of antiviral drugs approved over the past 50
years, shedding light on the development of effective antiviral
treatments against current and emerging infectious diseases
worldwide.
INTRODUCTION
Over the course of human civilization, viral infections havecaused millions of human casualties worldwide, driving the
development of antiviral drugs in a pressing need (1, 2). A new era
of antiviral drug development has begun since the first antiviral
drug, idoxuridine, was approved in June 1963 (3) (Fig. 1). Since
then, many antiviral drugs have been developed for clinical use to
treat millions of human beings worldwide. Between June 1963 and
April 2016, 90 drugs were formally approved to treat 9 human
infectious diseases (Table 1) despite the fact that thousands of
antiviral inhibitors have been proposed in the literature. Previ-
ously, we reviewed the history of 25 approved antiretroviral drugs
over 25 years (1984 to 2009) (4, 5). The present study commem-
orates 90 antiviral drugs approved for the treatment of 9 human
infectious diseases over the past 5 decades.
Approved antiviral drugs could be arbitrarily divided in 13
functional groups: (i) 5-substituted 2=-deoxyuridine analogues
(n  3 drugs and drug combinations); (ii) nucleoside analogues
(n 3); (iii) (nonnucleoside) pyrophosphate analogues (n 1);
(iv) nucleoside reverse transcriptase (RT) inhibitors (NRTIs) (n
9); (v) nonnucleoside reverse transcriptase inhibitors (NNRTIs)
(n  5); (vi) protease inhibitors (PIs) (n  19); (vii) integrase
inhibitors (n  5); (viii) entry inhibitors (n  7); (ix) acyclic
guanosine analogues (n 6); (x) acyclic nucleoside phosphonate
(ANP) analogues (n 10); (xi) hepatitis C virus (HCV) NS5A and
NS5B inhibitors (n 8); (xii) influenza virus inhibitors (n 8);
and (xiii) immunostimulators, interferons, oligonucleotides, and
antimitotic inhibitors (n  8). The inhibitory spectrum of these
approved drugs against 9 human infectious diseases can be sum-
marized as follows: human immunodeficiency virus (HIV)
(groups iv, v, vi, vii, viii, and x), human cytomegalovirus (HCMV)
(groups iii, ix, x, and xiii), hepatitis B virus (HBV) (groups ii, iv, x,
and xiii), HCV (groups vi, xi, xii, and xiii), herpes simplex virus
(HSV) (groups i, ii, iii, viii, and ix), influenza virus (group xii),
respiratory syncytial virus (RSV) (groups viii and xii), varicella-
zoster virus (VZV) (groups i, ii, viii, and ix), and human papillo-
mavirus (HPV) (group xiii). Table 2 summarizes the information
on antiviral drugs regarding their approval dates and mechanisms
of drug action. Table S1 in the supplemental material provides
details on drug databases and chemical formulas.
Nine human viruses can be classified into DNA viruses (HBV,
HCMV, HSV, HPV, and VZV), RNA viruses (HCV, RSV, and
influenza virus), and retroviruses (HIV) (Fig. 2). Interestingly, 11
of 90 antiviral drugs have been approved for the treatment of more
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FIG 1 History of antiviral drugs approved between January 1959 and April 2016. (A) Approved antiviral drugs visualized in the zodiac. The gray arrow shows
the dates of approval of antiviral drugs from January 1959 to April 2016. Twelve signs are positioned in a circle. Each sign indicates a drug group whose name is
annotated outside the circle. In the drug group, each red star within a sign represents an approved drug, placed according to the year of approval. Yellow stars
indicate approved drugs that have been discontinued or abandoned for clinical use. A total of 90 stars thus represent all approved antiviral drugs, and each drug
star is positioned according to its approval date (Table 2). In this picture, every approved drug could be conceived as a “superstar,” and its contribution to human
health is worthy of being remembered and respected. Therefore, this zodiac-based figure metaphorically recognizes each antiviral drug as a star in the universe,
commemorating the significant contributions of antiviral drug discovery and development over the past 50 years. A list of drug abbreviations is available in Table
2. Movies and label information for approved drugs are accessible online (see http://www.virusface.com/). (B) Timeline of approval of drugs against 9 human
infectious diseases (HIV, HBV, HCV, HSV, HCMV, HPV, RSV, VZV, and influenza virus). The x axis indicates the period from January 1959 to April 2016, and
the y axis shows the total number of approved drugs. For each virus, a colored line demonstrates the total number of approved drugs. Moreover, years of discovery
of HBV (1963), HPV (1965), HIV (1983), and HCV (1989) are indicated, while the other five viruses were discovered before 1959 (Table 1).
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than one infectious disease (Table 2), suggesting that antiviral
drugs may potentially treat multiple viral infections. Ribavirin, for
instance, is effective against three RNA viruses: HCV, RSV, and
influenza virus (Fig. 3). More importantly, antiviral drugs from
the same drug group share similar mechanisms of drug action to
inhibit viral replication during the viral life cycle (Fig. 4). In some
cases, approved antiviral drugs could be used as off-label treat-
ments for emerging infectious diseases. Therefore, a comprehen-
sive review that summarizes all approved antiviral drugs will shed
light on the development of novel inhibitors against current and
emerging viral infections.
In this review, we first give an overview of 9 human viruses.
Subsequently, the following three perspectives of 90 approved
drugs are discussed. (i) How were they discovered, and against
which viral infections are they active? (ii) How do they achieve their
mechanisms of action to target viral or host proteins? (iii) What ther-
apeutic aspects do they have? In addition, we make a summary of
promising antiviral compounds in phase 3 clinical trials (Table 3). To
give a comprehensive overview, we highlight the latest progress on
antiviral drugs and vaccines against emerging infectious diseases.
Challenges in the field of antiviral drug discovery are envisioned at the
end. To support this review, we have also established an online plat-
form (http://www.virusface.com/) to update the therapeutic aspects
of antiviral drugs and vaccines.
OVERVIEW OF NINE HUMAN VIRUSES
As of April 2016, antiviral drugs have been approved to treat 9
human infectious diseases (HIV, HBV, HCV, HCMV, HSV, HPV,
RSV, VZV, and influenza virus), albeit more than 200 human
viruses have been discovered (6). Below, we give an overview of
the origins, pathogenicities, epidemiologies, and clinical compli-
cations of these 9 human viruses.
Human Immunodeﬁciency Virus
Discovered in 1983 (7), HIV, a lentivirus in the Retroviridae fam-
ily, is the causative agent of AIDS (8). An HIV particle, which is
145 nm (range, 95 to 166 nm) in diameter (9), contains a linear
single-stranded RNA (ssRNA) genome encoding 15 mature viral
proteins (10) (Table 1). HIV strains can be classified into two types
(HIV-1 and HIV-2), which are further divided into extensive
groups, subtypes, and recombinant forms (for a review, see refer-
ence 11). A high level of genetic variation has been observed in the
HIV genome, making HIV one of the fastest-evolving organisms
(12). It has been estimated that the nucleotide diversity of HIV
genomes is almost 50% between HIV-1 and HIV-2, 37.5% be-
tween HIV-1 groups, and 14.7% between HIV-1 subtypes (10).
Regarding the origin of HIV, it can be traced to West Central
Africa in the late 19th or the early 20th century, when the butch-
ering and consumption of primate bushmeat were widely prac-
ticed (11, 13). Due to multiple zoonotic transfers, HIV is known to
be transmitted from chimpanzees (HIV-1 groups M and N), go-
rillas (HIV-1 groups P and O), and sooty mangabeys (HIV-2) to
humans (11, 14–16) (Fig. 2). As a blood-borne virus, HIV is
spread mainly through HIV-contaminated blood or body fluids;
thereby, patients can become infected with HIV by sexual contact,
needle sharing, blood transfusions, or maternal transmissions.
During chronic infection, the incubation period of HIV can be 8
to 11 years (17). Many clinical complications have been reported:
lymphoma, psychiatric disorders, gingivitis, cardiovascular dis-
ease, lung cancer, kidney disease, osteoporosis, papulosquamousT
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disorders, and dental or salivary gland diseases (for a review, see
reference 18). In the past 3 decades, HIV has caused a great burden
to global wealth and health. According to the WHO global health
survey,36.9 million (range, 34.3 million to 41.4 million) people
were infected with HIV, causing 1.2 million (range, 1.0 million to
1.5 million) deaths in 2014.
Hepatitis C Virus
Discovered in 1989 (19), HCV is a hepacivirus in the Flaviviridae
family (Fig. 2). An HCV particle, which is68 nm (range, 45 to 86
nm) in diameter (20), contains a linear, positive-sense, single-
stranded RNA genome encoding 10 viral proteins (21). HCV
strains can be classified into 7 major genotypes (genotypes 1 to 7),
among which genotypes 1 and 2 cause most infections worldwide
(22). It has been estimated that the nucleotide diversity of HCV
genomes is about 32.4% between HCV genotypes and 14.6%
within HCV genotypes (23). Regarding the origin of HCV, it re-
mains a mystery, but nonhuman primates (apes and monkeys)
and mammals (e.g., horses and dogs) might have been potential
zoonotic reservoirs (24). As a blood-borne virus, HCV is trans-
mitted mainly by sexual contact, needle sharing, blood transfu-
sions, or maternal transmissions. During acute infection, the in-
cubation period of HCV is7 weeks (range, 4 to 20 weeks) (25).
Many clinical complications have been observed, including liver
cirrhosis, liver failure, portal hypertension, or hepatocellular car-
cinoma (26, 27). HCV is also known to cause liver cancers such as
hepatocellular carcinoma (28). According to the WHO global
health survey, HCV causes 500,000 deaths every year, and 130
million to 150 million people were living with HCV in 2014.
Inﬂuenza Virus
Human influenza viruses from the Orthomyxoviridae family (Fig.
2) caused the first recognizable influenza pandemic in the summer
of 1510 (29, 30), and they were isolated for the first time in 1933
(31). A viral particle of influenza virus, which is120 nm (range,
84 to 170 nm) in diameter (32), contains a linear, negative-sense,
single-stranded RNA genome that encodes 11 or 12 proteins de-
pending on the virus strain (33). Influenza viruses can be classified
into three types: types A, B, and C. Influenza A viruses that cause
human epidemics and pandemics (e.g., Spanish flu in 1918, Asian
flu in 1957, and Hong Kong flu in 1968) are further divided into
extensive subtypes (i.e., H1N1, H1N2, or H3N2) based on the se-
quence variation of hemagglutinin (HA) and neuraminidase (NA),
two glycoproteins of the influenza virus membrane (34, 35). Influ-
enza B viruses that cause human epidemics are divided into strains
but not subtypes. Influenza C viruses cause neither epidemics nor
pandemics, because they usually infect humans with mild illnesses.
On the other hand, influenza viruses have been discovered in a broad
spectrum of animal reservoirs (36). Influenza A viruses can be trans-
mitted from animal reservoirs such as birds (e.g., H2N2, H5N1,
H7N3, and H9N2), pigs (e.g., H1N1 and H3N2), or seals (H7N7) to
humans (36). Using respiratory routes, influenza viruses spread
mostly through direct contact with contaminated aerosols or drop-
lets. During influenza infection, the typical incubation period is1 to
4 days (average, 2 days), and many clinical complications (e.g., pneu-
monia, bronchitis, dehydration, encephalitis, sinusitis, and ear infec-
tions) have been reported (see http://www.cdc.gov/). According to
the WHO global health survey, influenza viruses cause 250,000 to
500,000 deaths every year, and 3 million to 5 million cases of severe
illnesses were reported in 2014.
Respiratory Syncytial Virus
Discovered in 1957 (37), human RSV belongs to the Pneumovirus
genus in the Paramyxoviridae family (Fig. 2). An RSV particle,
which is 100 to 1,000 nm in diameter (38), contains a linear,
negative-sense, single-stranded RNA genome encoding 11 viral
proteins (39). RSV strains can be classified into two antigenic sub-
types, subtypes A and B, which are further divided into 11 RSV-A
and 23 RSV-B genotypes (40). Similar to influenza viruses, RSV
takes respiratory routes for its transmission, mainly by direct con-
tact with contaminated aerosols or droplets. Nevertheless, there is
no animal reservoir for human RSV (41). During human RSV
infection, the incubation period is 5 days (range, 3 to 8 days)
(42), and many clinical complications (e.g., respiratory tract dis-
eases, sinusitis, otitis bronchiolitis, and pneumonia) have been
observed (see http://www.cdc.gov/). Regarding the burden of
RSV, it causes 66,000 to 199,000 deaths every year. In 2005, RSV
infections caused 33.8 million cases of RSV-associated acute lower
respiratory infections among children5 years of age (43).
Hepatitis B Virus
Discovered in 1963 (44), HBV belongs to the Orthohepadnavirus
genus in the Hepadnaviridae family (Fig. 2). An HBV particle,
which is42 to 46 nm in diameter (45), contains a circular dou-
ble-stranded DNA (dsDNA) genome encoding 6 viral proteins.
HBV strains have been classified into 8 genotypes, further divided
into more than 24 subtypes. It has been estimated that the nucle-
otide diversity of HBV genomes is 14.5% between HBV geno-
types and 2.8% within HBV genotypes (46). Regarding the origin
of HBV, it remains a mystery to be unveiled, but bats might have
been the ancestral sources of primate hepadnaviruses (47, 48). As
a blood-borne virus, HBV can be transmitted by sexual contact,
needle sharing, blood transfusions, or maternal transmissions.
The incubation period of HBV infections is90 days (range, 60 to
150 days) (49). Major clinical complications of HBV infections
have been observed, such as hepatitis, anorexia, abdominal dis-
comfort, nausea, vomiting, arthralgia, rash, or liver cancer (see
http://www.cdc.gov/). HBV is also known to cause liver cancers
(e.g., hepatocellular carcinoma) (28). According to the WHO
global health survey, HBV causes 780,000 deaths every year, and
240 million people were infected in 2014.
Human Papillomavirus
Discovered in 1965 (50), HPVs from the Papillomaviridae family
are the causative agents of 90% of cervical cancers, the second
most common cancer among women worldwide (51). An HPV
particle, which is 65 to 120 nm in diameter (52), contains a
closed, circular, double-stranded DNA genome encoding 9 viral
proteins (53). HPV strains can be classified into200 types based
on the sequence variation of a late region encoding the capsid
protein L1 (54). HPV infections are responsible for 5% of hu-
man cancers (e.g., cervical carcinoma, anal carcinoma, and penile
carcinoma) (28, 55). Particularly, high-risk HPV type 16 (HPV-
16) and HPV-18 are known to cause 70% of cervical cancers, while
low-risk HPV-6 and HPV-11 cause 90% of external genital warts
(56) as well as most cases of recurrent respiratory papillomatosis
(57). Papillomaviruses have been widely found in birds, reptiles,
marsupials, and mammals, but cross-transfer between species is
rare (54). The incubation period from HPV infection to clinical
warts varies, and the average time is2.9 months (range, 0.5 to 8
months) (58). HPV infections are transmitted mainly through
Approved Antiviral Drugs
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intimate skin-to-skin contact. Regarding epidemiology, the
worldwide prevalence of HPV in women without cervical abnor-
malities is11% to 12% (59), and HPV is responsible for cervical
cancers, causing 266,000 deaths and 528,000 new cases in 2012
(see http://www.who.int/).
Human Cytomegalovirus
Discovered in 1956 (60), HCMV belongs to the Cytomegalovirus
genus in the Herpesviridae family (Fig. 2). An HCMV particle,
which is150 to 200 nm in diameter (61), contains a linear dou-
ble-stranded DNA genome harboring 200 to 250 open reading
frames (62). HCMV strains can be classified into four genotypes
(gB1, gB2, gB3, and gB4) based on the sequence variation of the
UL55 gene encoding glycoprotein B (gB) (63). In the absence of
any animal reservoir, HCMV circulates exclusively in human pop-
ulations (64). As a blood-borne virus, HCMV can be transmitted
through blood transfusions, body fluids, breastfeeding, organ
transplants, or sexual contact. Notably, the incubation period of
HCMV infections is 3 to 12 weeks. During HCMV infections,
many clinical complications have been observed, such as gastro-
intestinal diseases, mononucleosis, carditis, colitis, antigenemia,
ependymitis, esophagitis, encephalitis, retinitis, hepatitis, nephri-
tis, pancreatitis, pneumonia, allograft infections, or central ner-
vous system diseases (65, 66). Moreover, HCMV infections are
associated with high morbidity and mortality rates in solid-organ
transplant and hematopoietic stem cell transplant recipients (67,
68). Regarding epidemiology, the seroprevalence of HCMV in
worldwide populations is between 30% and 95% (69), the per-
centage of symptomatic children with permanent sequelae is
40% to 58% (70), and the prevalence of congenital HCMV at
birth is estimated to be 0.64% (range, 0.60 to 0.69%) (71).
Herpes Simplex Virus
Discovered before 1900 (72), HSV belongs to the Simplexvirus
genus in the Herpesviridae family (Fig. 2). An HSV particle, which
is 225 nm (range, 209 to 239 nm) in diameter (61), contains a
linear double-stranded DNA genome carrying 84 genes (73). HSV
can be classified into two types: HSV-1 and HSV-2. The former
leads to the majority of cases of oral herpes infections that cause
skin lesions and cold sores. The latter is mainly responsible for
genital herpes infections that cause pain during urination and
blistering sores. In the absence of any animal reservoir, HSV cir-
culates exclusively in human populations (74). HSV-1 transmis-
sions are mediated by direct exposure to contaminated aerosols or
droplets, such as oral-to-oral and skin-to-skin contacts. HSV-2 is
transmitted mainly by direct exposure to genital skin or fluids of
HSV-infected patients. During viral infections, the incubation pe-
riod of HSV-1 or HSV-2 is 4 days (range, 2 to 12 days) (75).
HSV-1 usually causes pneumonia, keratitis, encephalitis, or oro-
facial blisters, while HSV-2 typically causes meningitis or genital
lesions (74). According to the WHO global health survey, in 2012,
140 million and 417 million people between 15 and 49 years of age
lived with HSV-1 and HSV-2, respectively.
Varicella-Zoster Virus
Isolated in tissue culture for the first time in 1953 (76), VZV be-
longs to the Varicellovirus genus in the Herpesviridae family (Fig.
2). A VZV particle, which is 150 to 200 nm in diameter (77),
contains a linear double-stranded DNA genome carrying 73 genes
(78). VZV strains can be classified into five clades, clades 1 to 5,
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FIG 2 Virus family, morphology, and transmission of HIV, HBV, HCV, HSV, HCMV, HPV, RSV, VZV, and influenza virus. Nine human viruses are classified
into DNA viruses (HBV, HCMV, HSV, HPV, and VZV), RNA viruses (HCV, RSV, and influenza virus), and retroviruses (HIV). These viruses are from 7 families:
the Hepadnaviridae (HBV), the Papillomaviridae (HPV), the Herpesviridae (HCMV, HSV, and VZV), the Flaviviridae (HCV), the Paramyxoviridae (RSV), the
Orthomyxoviridae (influenza virus), and theRetroviridae (HIV). Schematic views and electron micrograph images of viral particles are illustrated in boxes, where
particle sizes measured as diameters and viral genome types (circular/linear dsDNA or linear RNA) are also indicated (Table 1). Human viruses are further
characterized with the possible animal reservoirs. HIV is known to be transmitted from chimpanzees (HIV-1 groups M and N), gorillas (HIV-1 groups P and O),
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which are further divided into 9 genotypes (78, 79). In the absence
of any animal reservoir, VZV circulates exclusively in human pop-
ulations (80). VZV is transmitted mostly by respiratory routes,
such as by direct contact with respiratory tract secretions (e.g.,
aerosols and droplets) or lesions. VZV infections, whose incuba-
tion period is10 to 21 days (81), are known to cause chickenpox
as well as a painful skin rash called shingles or herpes zoster (82).
Many clinical complications of herpes zoster in immunocompe-
or sooty mangabeys (HIV-2) (11, 14, 15). Influenza viruses that infect humans originate mostly from birds, pigs, or seals (36, 401). Although the origin of HBV
has yet to be clarified, bats might be a potential reservoir for HBV (47). HPV has been widely found in birds, reptiles, marsupials, and mammals, but cross-transfer
between species is rare (54). Four human viruses (RSV [41], HCMV [64], HSV [74], and VZV [80]) circulate only in human populations and do not have any
animal reservoir. In addition, it remains unclear whether HCV has any animal reservoir (27, 476). (The HCV electron micrograph image is republished from
reference 20 with permission of the publisher. The HPV electron micrograph image was obtained from the Laboratory of Tumor Virus Biology at the National
Cancer Institute [https://visualsonline.cancer.gov/]. The electron micrograph images for HBV, HCMV [by Sylvia Whitfield], HSV [by Fred Murphy and Sylvia
Whitfield], VZV [by Erskine L. Palmer and B. G. Partin], RSV [by Erskine L. Palmer], influenza virus [by Erskine L. Palmer and M. L. Martin], and HIV [by
Maureen Metcalfe and Tom Hodge] were obtained from the Centers for Disease Control and Prevention [http://phil.cdc.gov/phil/home.asp].)
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tent humans have been reported, including pneumonia, cellulitis,
neuralgia, encephalitis, myelitis, cranial nerve palsies, or periph-
eral nerve palsies (83). It has been estimated that 30% of humans
have been infected with herpes zoster over their lifetime (83), and
the seroprevalence of immunoglobulin G (IgG) antibody to vari-
cella-zoster virus is 86% in children and adults (84). In the
United States, VZV infections give rise to 1 million cases or more
each year (83, 85).
The nine human viruses described above have caused devastat-
ing infectious diseases that afflict millions of humans worldwide
(Table 1), therefore calling for the urgent development of effective
antiviral drugs. The following sections focus on the molecular and
therapeutic aspects of approved antiviral drugs against these 9
human viruses.
5-SUBSTITUTED 2=-DEOXYURIDINE ANALOGUES
Three antiviral drugs (idoxuridine, trifluridine, and brivudine
[BVDU]) have been approved in the drug group of 5-substituted
2=-deoxyuridine analogues (Table 2). Historically, the era of anti-
viral chemotherapies started in 1959 with the description of
idoxuridine (5-iodo-2=-deoxyuridine) by William H. Prusoff
(86). Although idoxuridine was originally described as a potential
antitumor agent, it would later become the first antiviral drug to
be used (and it still is) clinically for the topical treatment of her-
petic eye infection (i.e., keratitis due to HSV). Herrmann was the
first to report the antiviral activity of idoxuridine against HSV and
vaccinia virus in 1961 (87). Herrmann was also the first to propose
the use of idoxuridine against HSV keratitis in rabbits (88) and
humans (89). Thereafter, Kaufman and Heidelberger described
the effectiveness of trifluridine (5-trifluoromethyl-2=-deoxythy-
midine) against HSV infections (90). Idoxuridine and trifluridine
are now used for the topical treatment (such as in eye drops or eye
ointment) of HSV epithelial keratitis (91).
Idoxuridine and trifluridine alone cannot be considered spe-
cific antiviral agents, for they must be phosphorylated by cellular
kinases to either the 5=-triphosphate (TP) form (i.e., idoxuridine)
or the 5=-monophosphate form (i.e., trifluridine), both of which
actively inhibit viral and cellular DNA synthesis (3) (Fig. 5). As an
analogue of the nucleoside thymidine, brivudine [(E)-5-(2-bro-
movinyl)-2=-deoxyuridine] is highly specific in its activity against
HSV-1 and VZV (92, 93). Moreover, brivudine is superior to ei-
ther idoxuridine, trifluridine, or acyclovir in cell culture experi-
ments (94). To achieve its inhibitory activity, brivudine is specif-
ically phosphorylated by the thymidine kinases of HSV-1 and
VZV, which convert brivudine to its 5=-mono- and 5=-diphos-
phate forms. The cellular nucleoside 5=-diphosphate kinases fur-
ther phosphorylate the 5=-mono- and 5=-diphosphates of brivu-
dine into the 5=-triphosphate of brivudine, which targets the viral
DNA polymerase for the inhibition of viral DNA synthesis (92).
BVDU has been approved in many countries all over the world
(except for the United States and the United Kingdom) for the oral
treatment of VZV infections, i.e., herpes zoster (shingles), for
which it is prescribed at a dosage of 125 mg per day (for 7 days).
Moreover, brivudine is used as eye drops for the treatment of
HSV-1 epithelial keratitis. A systematic review, which collected
data from 106 comparative treatment trials enrolling 5,872 cases
with HSV infections, demonstrated that treatment with brivudine
at 14 days was at least as effective as acyclovir and ganciclovir, two
acyclic guanosine analogues (91). Ophthalmic preparations of
brivudine, trifluridine, acyclovir, and ganciclovir are equally effec-
tive, allowing90% of treated eyes to recover within 2 weeks (91).
Unlike idoxuridine and trifluridine, which cause high toxicity,
brivudine has a favorable safety profile and can be administered
systemically to treat HSV-1 and VZV (93). Moreover, brivudine
might be used to treat Epstein-Barr virus (EBV) encephalitis (95,
96), but this new application has yet to be proven in clinical trials.
NUCLEOSIDE ANALOGUES
The drug group of nucleoside analogues includes three FDA-ap-
proved drugs: vidarabine, entecavir (ETV), and telbivudine (Ta-
ble 2). Historically, arabinosyl nucleoside analogues were first iso-
lated from sponges (97). Before Schabel (98) documented its
antiviral potential, arabinosyladenine was first considered to be a
potential anticancer agent (99). With high potency against HSV
and VZV (e.g., herpes zoster) infections, vidarabine, which targets
viral DNA polymerases (Fig. 5), was the first of the FDA-approved
nucleoside analogues to be administered systemically in clinics
(100, 101). However, vidarabine is barely soluble in aqueous me-
dium, and it is rapidly deaminated by adenosine deaminases to its
inosine counterpart (ara-Hx [arabinosylhypoxanthine]). Since
TABLE 3 Summary of forthcoming antiviral treatments in phase 3 trials
Antiviral drug Viral infection % efficacya Mechanism(s) of action Study progressb
Sofosbuvir velpatasvir HCV genotypes 1–6 97.4 Inhibit activities of HCV NS5B polymerase
and NS5A, respectively
Phase 3, completed
Daclatasvir asunaprevir HCV genotype 1 86.4 Daclatasvir, asunaprevir, and beclabuvir
inhibit activities of NS5A, NS3/4A
protease, and NS5B, respectively
Phase 4, ongoing
Daclatasvir asunaprevir beclabuvir HCV genotype 1 91.5 Phase 3, ongoing
FV100 VZV 87.6 Inhibits activity of the VZV DNA
polymerasec
Phase 3, ongoing
Letermovir HCMV 71 Targets the pUL56 subunit of the HCMV
terminase complex to block viral DNA
processing and/or packagingd
Phase 3, ongoing
a For HCV inhibitors, drug efficacy is measured by the SVR12 (see the text). For the VZV inhibitor FV100, drug efficacy is measured by the incidence of patients without
postherpetic neuralgia after treatment at 90 days. For the HCMV inhibitor letermovir, drug efficacy is measured by the incidence of successful prophylaxis after treatment at 12
weeks (392).
b Clinical data were extracted from ClinicalTrials.gov (see https://www.clinicaltrials.gov/) in April 2016.
c See reference 385.
d See references 389 and 390.
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FIG 5 HCMV and HSV-1 DNA polymerase structures and chemical formulas of pyrophosphate analogues, 5-substituted 2=-deoxyuridine analogues, and
nucleoside analogues. (A) Tertiary structures of HCMV DNA polymerase in complex with dsDNA and foscarnet (PDB accession number 3KD5). HCMV DNA
polymerase is shown in pink. The dsDNA is placed in the center, where foscarnet inhibits DNA synthesis at the active site of HCMV DNA polymerase. Structural
movies that demonstrate drug binding are available online (see http://www.virusface.com/). PyMOL V1.7 visualization software (http://www.pymol.org/) was
used. (B) Tertiary structures of HSV-1 DNA polymerase complexed with dsDNA and ATP (PDB accession numbers 2GV9 and 4M3R). HSV-1 DNA polymerase
is shown in pink. ATP near the catalytic site is displayed in the drug-binding pocket. The triphosphate form of approved antiviral inhibitors (e.g., vidarabine
triphosphate) can compete with dATP to inhibit the replication activity of HSV DNA polymerase. (C) Chemical formula of foscarnet in the group of pyrophos-
phate analogues. (D to F) Chemical formulas of idoxuridine, trifluridine, and brivudine in the group of 5-substituted 2=-deoxyuridine analogues. (G to J)
Chemical formulas of telbivudine, entecavir, vidarabine, and FV100 in the group of nucleoside analogues. Note that FV100 is an experimental inhibitor in phase
3 clinical trials.
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June 2001, vidarabine has been discontinued in the United States,
probably for commercial reasons (102).
For the treatment of HBV infections, the following compounds
have been licensed: (pegylated) interferons, lamivudine, enteca-
vir, telbivudine, adefovir dipivoxil, and tenofovir disoproxil fu-
marate (TDF) (Table 2). Lamivudine and TDF have also been
licensed for the treatment of HIV infections and are further dis-
cussed below. Two nucleoside analogues, entecavir and telbivu-
dine, are exclusively used for the treatment of HBV infections (Fig.
5). In patients with either HBeAg-positive (HBeAg) chronic
hepatitis B (103) or HBeAg-negative chronic hepatitis B (104), the
rates of histological, virological, and biochemical improvements
were significantly higher with entecavir than with lamivudine.
More importantly, long-term monitoring of nucleoside-naive pa-
tients receiving 5 years of entecavir therapy showed a low rate of
HBV resistance to entecavir (105). However, it came as a surprise
when entecavir was reported to inhibit HIV-1 infections with only
modest activity (106, 107), because this might generate HIV-1
resistance to entecavir in patients coinfected with HIV-1 and
HBV. The “take-home” message was not to use entecavir in such
patients (107).
Several phase 2 or 3 clinical trials compared the potencies and
safeties of telbivudine versus lamivudine, and their findings sug-
gested that telbivudine offered greater HBV DNA suppression
with less resistance than did lamivudine (108–110). For instance, a
randomized, double-blind, phase 3 trial that enrolled 1,367 pa-
tients infected with chronic HBV suggested that telbivudine was
superior to lamivudine in terms of higher rates of undetectable
viremia and less resistance (111). For treatment of HBeAgmoth-
ers during late pregnancy, telbivudine was well tolerated, with no
severe side effects in telbivudine-treated mothers or their infants
(112). Although entecavir is superior to telbivudine in safety, both
telbivudine and entecavir offer similar drug efficacies in terms of
the cumulative rates of undetectable HBV DNA and alanine ami-
notransferase levels (113). For first-line therapy of HBV infec-
tions, the use of entecavir is strongly recommended, especially in
children aged 2 to 12 years (114). Nevertheless, telbivudine, lami-
vudine, and adefovir dipivoxil are not recommended because they
have a low barrier to resistance (114).
Overall, orally administered nucleos(t)ide analogues, with
their safety, easy use, and low drug resistance rates, are preferable
for HBV treatments, but the high costs of these drugs remain a
great concern in resource-limited areas. Therefore, lamivudine is
commonly used in first-line therapy regardless of its high rate of
drug resistance (115).
PYROPHOSPHATE ANALOGUES
Trisodium phosphonoformate, known as foscarnet (Fig. 5), was
discovered as a new antiviral compound in 1978 (116). Although
it is the only approved inhibitor in this drug group, foscarnet was
not the first pyrophosphate analogue, as it had been preceded by
phosphonoacetic acid (117). The novelty of foscarnet and phos-
phonoacetic acid depends on the fact that these compounds are
unlike other classical antiviral agents (i.e., BVDU and acyclovir),
because they do not have to be phosphorylated (i.e., metabolized
to their active metabolite) before their binding to drug targets (i.e.,
viral DNA polymerases) (118). Therefore, foscarnet could be se-
lected directly at the enzyme level (116).
In a comprehensive review, Bo O¨berg (119) ascertained that
foscarnet achieved its broad-spectrum activity against HSV-1,
HSV-2, VZV, HCMV, EBV, HIV, and HBV by targeting viral
DNA polymerases (Fig. 5). However, foscarnet neither showed
inhibitory activities against viral RNA polymerases nor inhibited
the replication of RNA viruses (except for retroviruses) (119).
Despite its inhibitory activity, specifically confined to DNA vi-
ruses and retroviruses, foscarnet acts in a unique fashion because
it binds directly, as a pyrophosphate analogue, to viral DNA poly-
merases (Fig. 5). Foscarnet is unlike nucleos(t)ide analogues that
must be phosphorylated to their triphosphate (nucleoside) or
diphosphate (nucleotide) forms before their binding to viral DNA
polymerase (Fig. 5).
Foscarnet is used exclusively in the treatment of HCMVs or
HSVs that have become resistant to the classical nucleoside ana-
logues such as acyclovir. As shown in some case reports, the effec-
tiveness of foscarnet has been demonstrated in the treatment of
infection by thymidine kinase-deficient HSV strains with resis-
tance to acyclovir (120–122). Clinical evidence also suggests that
foscarnet-based treatments efficiently improve the clinical out-
comes of HIV-infected patients with HSV infections (123). For
the treatment of HCMV infections, foscarnet-based regimens may
eradicate viremia rapidly, yet their efficacy is limited because of a
high level of toxicity in the long term (124). Common side effects
with foscarnet are nausea, diarrhea, vomiting, headache, renal im-
pairment, or ionized hypocalcemia (125, 126).
In addition to its antiviral activity against HCMV and HSV
infections, foscarnet is effective against human herpesvirus 6
(HHV-6), a widespread betaherpesvirus genetically related to
HCMV (127). Despite its promising activity against HHV-6, fos-
carnet has not been approved to treat HHV-6. Therefore, further
clinical trials will still be required to prove this potential in the
future.
NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
Soon after its discovery as an anti-HIV agent in 1985 (128), zid-
ovudine (AZT [azidothymidine]) was licensed for clinical use in
1987. Zidovudine is not only the first drug approved for HIV
treatment but also the first drug in the group of NRTIs, which
target HIV reverse transcriptase to interfere with viral reverse
transcription (Fig. 6). Inspired by the success of zidovudine, 6
drugs in the group of NRTIs (Fig. 6) were subsequently approved
to treat HIV or HBV infections: (i) didanosine (ddI [2=,3=-dide-
oxyinosine]) (129), (ii) zalcitabine (ddC [2=,3=-dideoxycytidine])
(129), (iii) stavudine (d4T [2=,3=-didehydro-3=-deoxythymi-
dine]) (130–132), (iv) lamivudine (3TC [2=,3=-dideoxy-3=-thiacy-
tidine]) (133), (v) abacavir (ABC) [(1S,4R)-4-(2-amino-6-(cyclo-
propylamino)-9H-purin-9-yl)-2-cyclopentene-1-methanol] (134),
and (vi) emtricitabine [()FTC (2=,3=-dideoxy-5-fluoro-3=-thia-
cytidine), where “()” indicates the L-enantiomeric form] (135).
All NRTI compounds are known as 2=,3=-dideoxynucleoside
analogues, with similar mechanisms of drug action. After their
phosphorylation to the 5=-TP, NRTIs act as chain terminators, a
mechanism of drug action originally shown for AZT (136), with
(i) AZT-TP in competition with dTTP (137), (ii) ddATP (formed
from ddI) in competition with dATP, (iii) ddCTP (formed from
ddC) in competition with dCTP, (iv) d4T-TP (formed from d4T)
in competition with dTTP, (v) 3TC-TP (formed from 3TC) in
competition with dCTP, (vi) carbovir-TP (formed from ABC) in
competition with dGTP, and (vii) ()FTC-TP [formed from
()FTC] in competition with dCTP (4) (Fig. 6).
NRTIs alone are not administered in HIV treatments because
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FIG 6 Tertiary structures of HIV-1 reverse transcriptase and chemical formulas of NRTIs and NNRTIs. (A) HIV-1 RT complexed with dsDNA and zidovudine
triphosphate (left) (PDB accession number 3V4I) and nevirapine (right) (PDB accession number 4PUO). Two subunits of the HIV-1 RT heterodimer are shown
in pink and orange, respectively. Zidovudine triphosphate targets the drug-binding pocket of NRTIs, known as the catalytic site, to inhibit the activity of HIV-1
RT during DNA synthesis. Nevirapine targets the drug-binding pocket of NNRTIs, known as the allosteric site, to block the activity of HIV-1 RT during DNA
synthesis (see structural movies at http://www.virusface.com/). (B to H) Chemical formulas of zidovudine, stavudine, zalcitabine, emtricitabine, didanosine,
lamivudine, and abacavir in the group of NRTIs. (I to M) Chemical formulas of delavirdine, nevirapine, efavirenz, rilpivirine, and etravirine in the group of
NNRTIs.
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NRTIs usually have a low genetic barrier to the development of
drug resistance mutations, which have been characterized by the
International Antiviral Society-USA (IAS-USA) panel (138) and
the HIV drug resistance database (http://hivdb.stanford.edu/).
NRTIs are commonly administered with other drugs in highly
active antiretroviral therapy (HAART) to target multiple stages of
the HIV life cycle (139, 140). In particular, both lamivudine and
emtricitabine are backbones in 9 approved combination drugs
(Table 2): (i) lamivudine plus zidovudine (Combivir); (ii) lami-
vudine plus zidovudine and ABC (Trizivir); (iii) lamivudine plus
the integrase inhibitor dolutegravir (Dutrebis); (iv) lamivudine
plus dolutegravir and abacavir (Triumeq); (iii) emtricitabine plus
TDF (Truvada); (iv) emtricitabine plus TDF and efavirenz
(Atripla); (v) emtricitabine plus TDF and the NNRTI rilpivirine
(Complera or Eviplera); (vi) emtricitabine plus TDF, the integrase
inhibitor elvitegravir, and cobicistat (Stribild); (vii) emtricitabine
plus tenofovir alafenamide (TAF), elvitegravir, and cobicistat
(Genvoya); (viii) emtricitabine plus TAF and rilpivirine (Odef-
sey); and (ix) emtricitabine plus TAF (Descovy). Although the
pharmacological equivalence and clinical interchangeability of
lamivudine and emtricitabine remain debated (141, 142), both
drugs are key components of approved combination drugs.
In clinical practice, the most common side effects with NRTIs
are reversible peripheral neuropathy, nausea, headache, rash, ane-
mia, leukopenia, pancreatitis, gout, or hypersensitivity (143). It is
also worth mentioning that because of its neurotoxicity, the FDA-
approved agent zalcitabine has been discontinued since December
2006. As of today, NRTI drugs, patented mostly before 2003, are
over their expiration dates for patents (144). Patent expiration
thus stimulates broad marketing worldwide, making NRTIs pop-
ular first-line agents against HIV infections in resource-limited
areas.
NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
Discovered in the late 1980s, the group of NNRTIs includes five
approved anti-HIV drugs: nevirapine, delavirdine, efavirenz, etra-
virine, and rilpivirine (Table 2). Historically, NNRTIs originated
from two classes of compounds discovered independently from
each other: 1-[(2-hydroxy-ethoxy)methyl]-6-phenylthiothymine
(HEPT) analogues (145, 146) and tetrahydro-imidazo[4,5,1-
jk][1,4]-benzodiazepine-2(1H)-one and -thione (TIBO) ana-
logues (147). To inhibit viral replication, HEPT and TIBO deriv-
atives target HIV-1 reverse transcriptase (148–150). Emivirine
(MKC-442), derived from the HEPT derivatives (151), had
reached phase 3 clinical trials before its further development was
stopped (152). TIBO derivatives led through a highly meandrous
route to the identification of diarylpyrimidine (DAPY) derivatives
(153), including dapivirine, etravirine, and rilpivirine (154). Ap-
proved by the FDA, etravirine (Intelence) and rilpivirine (Edu-
rant), accompanied by three other NNRTIs (delavirdine, efa-
virenz, and nevirapine), are now on the market. Delavirdine is
currently rarely used due to its high toxicity, relatively low po-
tency, and complex drug interactions (155).
Unlike NRTIs, NNRTIs do not need any metabolic processing
to inhibit HIV reverse transcription (Fig. 6). Instead, they serve as
noncompetitive inhibitors that target the allosteric site of HIV-1
RT, situated a short distance (15 Å) from the RT catalytic site
(156–158). This binding induces conformation changes to impair
the catalytic activity of HIV-1 RT, thus interrupting viral replica-
tion (159). Importantly, NNRTIs act specifically against HIV-1,
whereas HIV-2 is naturally resistant to all NNRTIs due to its struc-
tural properties (160). When RT structures of HIV-1 and HIV-2
were compared, differences were found at both conserved and
nonconserved positions (K101, V106, E138, Y181, Y188, and
G190) in the drug-binding pocket of NNRTIs (161). In addition to
the above-mentioned positions, drug resistance mutations at
other RT positions (V90, A98, L100, K103, V108, V179, H221,
P225, F227, and M230) may also cause treatment failure of
NNRTIs (138).
In clinical practice, NNRTIs are widely used as first-line agents.
They can be combined with tenofovir disoproxil fumarate,
()FTC, and rilpivirine to afford a once-daily pill, Complera
(United States) or Eviplera (European Union), for all-inclusive
treatments of HIV infections (153). The most common side effects
with NNRTIs are rash, central nervous system toxicity, or eleva-
tion of liver enzyme levels (143). Promising NNRTIs such as dora-
virine (MK-1439) (162–164) and diarylpyrimidine (165) are un-
der investigation in clinical trials.
PROTEASE INHIBITORS
In the group of protease inhibitors (PIs), 12 HIV protease com-
pounds and 7 HCV NS3/4A protease compounds have been ap-
proved for clinical use (Table 2). HIV and HCV protease inhibi-
tors are described below.
HIV Protease Inhibitors
Historically, HIV-1 protease (Fig. 7) was first proposed as a po-
tential target for AIDS therapy by Kramer et al. (166), when they
showed that a frameshift mutation in the protease region of the pol
gene prevented protease-mediated cleavage of gag precursor pro-
teins (167). The transition state mimetic concept later inspired
Roberts and coworkers to describe the rational design of peptide-
based protease inhibitors (167). In 1995, saquinavir was approved
as the first protease inhibitor, marking the beginning of an era for
this new class of anti-HIV inhibitors. In fact, not only saquinavir
but also 9 out of the 10 approved HIV protease inhibitors are
based on the same principle, in which the hydroxyethylene bond
acts as the peptidomimetic scaffold, including saquinavir, ritona-
vir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fos-
amprenavir, and darunavir (Fig. 7). The only exception is tiprana-
vir, which is built on the coumarin scaffold (168). When protease
inhibitors compete with natural substrates of HIV protease as the
peptidomimetic scaffold (169), amino acid variations near this
scaffold and within the cleavage sites of protease substrates (i.e.,
Gag and Gag-Pol) may have been selected during virus evolution
to cause resistance to HIV protease drugs (170, 171). Except for
the discontinued agent amprenavir (Agenerase), which is super-
seded by fosamprenavir, other protease inhibitors are still widely
used for HIV infections. Common side effects with PIs are neph-
rolithiasis, hypertension, rash, diarrhea, elevation of liver enzyme
levels, ingrown toenails, benign hyperbilirubinemia, and gastro-
intestinal upset (143).
HIV protease inhibitors are key components of HAART for
patients infected with HIV-1 and/or HIV-2. However, primary
and secondary resistance mutations in HIV protease remain a
concern for administering PIs to patients harboring drug-resis-
tant viruses (138, 169, 172). Because of the innate differences be-
tween HIV-1 and HIV-2 proteases (173), different PI-based treat-
ments have been recommended for HIV-1 and HIV-2 infections
to take resistance-associated mutation patterns into account
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FIG 7 Tertiary structures of HIV-1 protease and chemical formulas of HIV protease inhibitors. (A) HIV-1 protease dimer complexed with lopinavir (PDB
accession number 2Q5K). The side view (left) and top view (right) of structures are presented. (B to K) Chemical formulas of nelfinavir, saquinavir, indinavir,
atazanavir, lopinavir, ritonavir, fosamprenavir, amprenavir, darunavir, and tipranavir in the group of protease inhibitors. (L) Chemical formula of cobicistat.
Cobicistat is a pharmacoenhancer used with HIV protease inhibitors, but cobicistat alone shows no antiviral activity.
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(140). In contrast to the wide application of PIs approved for
HIV-1 infection, current U.S. and European treatment guidelines
recommend the use of lopinavir/ritonavir (LPV/r), saquinavir/
ritonavir (SQV/r), or darunavir/ritonavir (DRV/r) for patients
infected with HIV-2, because many polymorphisms in HIV-2
cause natural resistance to PIs such as tipranavir and fosamprena-
vir (140, 174, 175). Note that ritonavir is a popular booster that
improves the bioavailability and half-lives of other PIs, so a low
dose of ritonavir is commonly coadministered with other PIs (e.g.,
LPV/r) (169). In a similar fashion, cobicistat has been approved as
a pharmacoenhancer of PIs. Although it has no antiviral activity,
cobicistat inhibits intestinal transport proteins (cytochrome P450
enzymes of the CYP3A family) and increases the overall absorp-
tion of PIs (176). Approved by the FDA, cobicistat is now coad-
ministered with the PIs darunavir (Prezcobix) and atazanavir
(Evotaz) as well as other anti-HIV drugs (Stribild and Genvoya),
which are elucidated below.
HCV NS3/4A Protease Inhibitors
Despite fundamental differences in their structures and modes of
replication, HIV and HCV share some similarities because both
viruses cleave precursor proteins by viral proteases (aspartic pro-
tease for HIV versus serine protease for HCV) (Fig. 8), which
could serve as ideal targets for the design of protease inhibitors
(177). Of many protease inhibitor candidates, the following seven
compounds that efficiently inhibit the activity of HCV NS3/4A
protease are momentarily on the market (Fig. 8): asunaprevir,
boceprevir, paritaprevir, simeprevir, telaprevir, vaniprevir, and
grazoprevir (178–180). Among them, boceprevir (Victrelis) and
telaprevir (Incivek) were discontinued for commercial reasons.
To treat patients with HCV genotype 1 infection, combination
drugs of asunaprevir plus daclatasvir and vaniprevir plus pegy-
lated interferon alfa 2b (PegIFN-2b) plus ribavirin have been
approved in Japan (181).
All approved NS3/4A protease inhibitors are used for treatment
of infection by HCV genotype 1, the most prevalent genotype in
HCV-infected populations (182). Compared to two discontinued
drugs, telaprevir and boceprevir, simeprevir has better response
rates and drug interaction profiles, although it is more expensive.
As a potent inhibitor approved by the FDA, paritaprevir is now
used in combination with ombitasvir plus ritonavir (Viekira Pak)
or ombitasvir plus dasabuvir plus ritonavir (Technivie) to treat
HCV genotype 1 and 4 infections, respectively (Table 2). Ap-
proved by the FDA in January 2016, a combination drug of gra-
zoprevir plus elbasvir (Zepatier) is now applied to treat HCV ge-
notype 1 or 4 infection (Table 2). In addition to the approved
drugs mentioned above, many experimental NS3/4A protease
inhibitors (danoprevir, faldaprevir, vedroprevir, sovaprevir,
deldeprevir, and narlaprevir) have been (or still are) under clinical
development (178, 179). Forthcoming HCV protease inhibitors
may have a reduced potential for drug-drug interactions, thus
improving their use in the treatment of HCV infections (183).
INTEGRASE INHIBITORS
Since the first HIV integrase inhibitor was approved in 2007, three
FDA-approved integrase inhibitors (raltegravir, dolutegravir, and
elvitegravir) have been frequently used in HAART. Integrase in-
hibitors are described below.
Raltegravir
During virus integration, viral integrases insert proviral DNA into
host genomes through a multistep process. As an essential step,
the strand transfer reaction covalently links the proviral DNA 3=
ends to the cellular (target) DNA, and this strand transfer can be
inhibited by the so-called diketo acid inhibitors (184). These
diketo acids (i.e., L-870812) could actively suppress the replica-
tion of simian-human immunodeficiency virus (SHIV) in rhesus
macaques (185). This led to the discovery of raltegravir (MK-
0518) as the “first in class” among the integrase inhibitors, which
target the catalytic site of HIV integrase to prevent virus integra-
tion (Fig. 9). Raltegravir was later added to an optimized back-
ground regimen (OBR) (186), offering better virus suppression
than the OBR alone (187). The use of raltegravir was effective,
particularly for the treatment of HIV-infected patients with high
HIV-1 RNA levels, low CD4 cell counts, and low genotypic or
phenotypic sensitivity scores (188). Raltegravir could be com-
bined with two nucleos(t)ide analogues or with ritonavir-boosted
lopinavir (189). Since there is no raltegravir-based combination
approved by the FDA, the effectiveness of such combination drugs
has yet to be elucidated in clinical trials.
Elvitegravir
In 2006, Sato and coworkers first showed that the 4-quinolone-3-
carboxylic acids could be an alternative scaffold to diketo acids,
leading to the discovery of elvitegravir (GS-9137), which effi-
ciently inhibited the DNA strand transfer reaction of HIV-1 inte-
grase (190). Subsequent in vitro studies indicated that elvitegravir
inhibited not only strains of various HIV-1 subtypes but also a
broad spectrum of viruses such as HIV-2, murine leukemia virus,
and simian immunodeficiency virus (SIV) (191, 192). Akin to
raltegravir, elvitegravir can be used in combination with nucleos-
(t)ide analogues. Stribild, which contains elvitegravir, cobicistat,
()FTC, and TDF (193), was approved as the first once-daily
four-drug (“quad”) pill in August 2012. Stribild causes minimal
adverse effects but efficient virus suppression comparable to those
for other HIV combination drugs (e.g., Atripla) (194, 195). Ap-
proved in November 2015, Genvoya is another combination drug
that contains elvitegravir plus cobicistat, ()FTC, and tenofovir
alafenamide.
When the efficacy and safety of elvitegravir was compared with
those of raltegravir, a phase 3 clinical trial suggested that both
drugs are comparable, but elvitegravir might improve patients’
adherence because elvitegravir requires only once-daily dosing,
compared with twice-daily dosing for raltegravir (196). Elvitegra-
vir is usually well tolerated, while the most common side effects
are diarrhea and nausea (197). It is worth mentioning that elvite-
gravir should not be used to treat raltegravir-resistant HIV infec-
tions, because elvitegravir shares similar drug resistance muta-
tions with raltegravir (198).
Dolutegravir
Approved by the FDA in August 2013, dolutegravir is the third
integrase inhibitor on the market. Even though dolutegravir and
raltegravir share similar efficacies and safety profiles (199), do-
lutegravir exhibits a higher genetic barrier to drug resistance de-
velopment (200). Moreover, once-daily dolutegravir, in combina-
tion with up to two other antiretroviral drugs, provides a better
virologic response than twice-daily raltegravir in antiretroviral-
experienced patients (201). In a phase 3b clinical trial called
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FIG 8 Tertiary structures of HCV NS3/NS4B protease and chemical formulas of HCV protease inhibitors. (A) HCV NS3/NS4B protease in complex with
simeprevir (PDB accession numbers 3KEE and 4B76). HCV NS3 and NS4B proteins are shown in pink and orange, respectively. (B to H) Chemical formulas of
boceprevir, telaprevir, asunaprevir, simeprevir, paritaprevir, vaniprevir, and grazoprevir in the group of HCV protease inhibitors.
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FLAMINGO, once-daily dolutegravir was superior to once-daily
darunavir plus ritonavir for the treatment of antiretroviral-naive
patients infected with HIV-1 (202, 203). Due to its prominent
antiviral activity, dolutegravir is now used in two fixed-dose com-
binations: dolutegravir plus abacavir plus lamivudine (Triumeq)
(one tablet, once daily) and dolutegravir plus lamivudine (Du-
trebis) (one tablet, twice daily) (Table 2).
In first-line therapy, integrase inhibitors are superior to NRTIs,
NNRTIs, and protease inhibitors (200). Even though integrase
inhibitors have a high genetic barrier to resistance (200), drug
resistance mutations (e.g., F121Y, Q148H/R, N155H, and R263K)
have been observed for all three integrase inhibitors (138). The
most common side effects with integrase inhibitors are nausea,
diarrhea, hepatitis, or hypersensitivity (200). Attracted by their
potent antiviral activities, forthcoming integrase inhibitors are
under investigation in clinical trials. For instance, cabotegravir
(GSK1265744 and GSK744) has been recognized as a long-acting
inhibitor against the strand transfer reaction of HIV and SIV in-
tegrases (204–206). Recently, the potent anti-HIV activity of ther-
apy with cabotegravir plus rilpivirine was shown in a randomized,
phase 2b, dose-ranging trial (207), but more evidence is still re-
quired to support its clinical use. Overall, integrase inhibitors have
offered good tolerability, a favorable safety profile, and an absence
of significant drug interactions (200).
ENTRY INHIBITORS
In the drug group of entry inhibitors, there are 7 FDA-approved
drugs, including one HSV drug (docosanol), two HIV drugs (en-
fuvirtide and maraviroc), two RSV antibody drugs (palivizumab
and respiratory syncytial virus immune globulin, intravenous
[RSV-IGIV]), and two VZV antibody drugs (varicella-zoster im-
munoglobulin [VariZIG] and varicella-zoster immune globulin
[VZIG]) (Table 2). These entry inhibitors are described in the
following sections.
Enfuvirtide and Maraviroc
Enfuvirtide (also known as T20), the first peptide inhibitor ap-
proved by the FDA, is a polypeptide (36 amino acids in length)
homologous to the heptad repeat region of HIV-1 GP41 (208)
(Fig. 10). To block the fusion of HIV-1 with the extracellular
membrane of host cells, enfuvirtide mimics the helix in heptad
repeat 2 (HR-2) to prevent the interaction between HR-1 and
HR-2 (209, 210). Kilby et al. (211) showed the significant efficacy
of enfuvirtide against HIV-1 replication in cell lines and human
subjects. Approved by the FDA in March 2003, enfuvirtide is still
the only anti-HIV drug that must be injected subcutaneously
twice daily. It has been used for salvage therapies as part of com-
bination regimens with other antiviral drugs (212, 213). Although
enfuvirtide has high drug efficacy with minimal systemic toxicity,
its long-term application is limited due to the subcutaneous ad-
ministration and the high cost (214). The clinical use of enfu-
virtide has therefore become obsolete given the wealth of the other
40 approved drugs against HIV infections by oral drug delivery.
Maraviroc is the first FDA-approved chemokine receptor an-
tagonist or CCR5 inhibitor that targets the chemokine receptor
CCR5 on the surface of CD4 cells and macrophages (215)
FIG 9 Tertiary structures of viral integrase and chemical formulas of HIV integrase inhibitors. (A) Viral integrase of prototype foamy virus in complex with
dsDNA and dolutegravir (PDB accession number 3S3N). A dimer structure of the viral integrase is shown in pink and cyan, respectively. Although the structure
of HIV integrase in complex with its inhibitors is still lacking, approved antiviral inhibitors that target HIV and prototype foamy virus integrase are believed to
share similar mechanisms (477). (B to D) Chemical formulas of raltegravir, elvitegravir, and dolutegravir in the group of HIV integrase inhibitors.
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FIG 10 Chemical formulas of HIV entry inhibitors and tertiary structures of CCR5, HIV-1 GP41, and RSV glycoprotein F. (A) Chemical formula of docosanol.
(B and C) Chemical formula of maraviroc and the CCR5 coreceptor in complex with maraviroc (PDB accession number 4MBS). The top and side views of the
CCR5 structure are presented. (D and E) Chemical formula of enfuvirtide and tertiary structure of the HIV-1 GP41 trimer (PDB accession number 2X7R).
Enfuvirtide is derived from the green region of HIV-1 GP41. The top and side views of the HIV-1 GP41 trimer are presented. Three units of the HIV-1 GP41 trimer are
shown in blue, red, and pink, respectively. (F) Tertiary structure of the prefusion RSV glycoprotein F trimer in complex with the antibody motavizumab (PDB accession
number 4ZYP). Motavizumab is an experimental monoclonal antibody derived from the FDA-approved drug palivizumab (478). The side views (left) and top views
(right) of protein structures are presented. The heavy and light chains of motavizumab are shown in blue and green, respectively. The palivizumab-binding site (amino
acid [aa] positions 254 to 277 [479]) is highlighted in red. Three units of the prefusion RSV F trimer are shown in pink, gray, and cyan, respectively.
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(Fig. 10). Historically, Ed Berger and colleagues were the first to
demonstrate the importance of the CC chemokine receptor CCR5
during HIV entry (216). Baba et al. (217) were the pioneers who
described the first CCR5 antagonist, TAK-779, which, however,
was not pursued due to its poor oral bioavailability. Likewise,
TAK-220 and TAK-652, despite their oral bioavailability (218),
were not developed further, nor were two CCR5 antagonists, apla-
viroc and vicriviroc (219). Later, the principle of attacking CCR5
was proven to be a success when maraviroc showed promising
antiviral activities in cell lines (220) and clinical trials (221, 222). It
is worth mentioning that during early HIV infection, R5 viruses
predominately use CCR5 for virus entry, whereas R4 viruses using
CXCR4 usually occur at late stages of disease progression (223).
For patients with R5 HIV-1 infections, maraviroc is a valuable
treatment option (222, 224). However, maraviroc does not inhibit
R4 viruses, and half of patients infected with R4 viruses fail mara-
viroc-based treatments (225). Therefore, it is possible that CCR5
antagonists would accelerate disease progression by the selection
of viruses using CXCR4 (214, 215). Overall, the use of maraviroc
requires the phenotypic identification of R5 viruses, and the co-
administration of CCR5 and CXCR4 antagonists has yet to be a
therapeutic challenge (214, 226).
Palivizumab and RSV-IGIV
RSV-IGIV, approved by the FDA in January 1996, is a sterile hu-
man immunoglobulin produced from adult plasma with high ti-
ters of neutralizing antibodies to RSV (227). These neutralizing
antibodies can prevent RSV surface glycoproteins F and G from
anchoring to host cells (227). Although RSV-IGIV may efficiently
decrease the numbers of hospitalizations and hospital days attrib-
utable to RSV (228), the high cost and strict guidelines on its use
remain a problematic issue (229). As a more cost-effective drug
(230), palivizumab (Synagis) marked the discontinuation of
RespiGam in 2004 (231). Approved by the FDA in June 1998,
palivizumab is a humanized mouse immunoglobulin monoclonal
antibody that directly targets a conserved epitope of the A anti-
genic site of the RSV fusion protein (232) (Fig. 10F). Therefore,
palivizumab offers neutralizing and fusion-inhibitory activities
against RSV infections (232). In clinical practice, palivizumab
prophylaxis is recommended only for preterm infants with
chronic lung diseases or congenital heart diseases, mostly in the
first year of life for infants born within 12 months of the onset of
the RSV season (232). Despite the promising outcomes from clin-
ical trials (233, 234), systematic reviews suggest that the limited
clinical and social benefits are insufficient to justify the high cost of
palivizumab prophylaxis (232, 235, 236). Consequently, the clin-
ical use of palivizumab prophylaxis is not popular in most cases.
VZIG and VariZIG
Historically, VZIG was discovered in 1969 when immunoglobulin
concentrates were extracted from patients convalescing from VZV
infections. Subsequent serological and clinical studies suggested
that VZIG could decrease the risk of complications and reduce
clinical illness in immunocompromised patients (237, 238). After
its application for 2 decades, VZIG was discontinued in October
2004 and was later superseded by a better product, called VariZIG.
Approved by the FDA in December 2012, VariZIG is a detergent-
treated, sterile, lyophilized preparation of IgG purified from hu-
man plasma harboring high levels of anti-VZV antibodies.
VariZIG offers passive immunization for immunocompromised
patients to generate IgG antibodies against VZV infections (239).
Licensed for postexposure prophylaxis of VZV infections,
VariZIG is administered intramuscularly to high-risk patients
who lack evidence of immunity to VZV and are ineligible for VZV
vaccination (240). VariZIG must be administered to patients
within 96 h of exposure to VZV, and the dosing of VariZIG de-
pends on body weight. Common side effects with VariZIG are
headache and pain at the injection site. Overall, VariZIG offers a
cornerstone for VZV postexposure prophylaxis, while approved
antiviral drugs such as acyclovir are also recommended to be used
either alone or with immunoglobulin therapy (81).
Docosanol
Docosanol (n-docosanol; behenyl alcohol) is a 22-carbon, satu-
rated, primary alcohol (Fig. 10) that inhibits a broad spectrum of
lipid-enveloped viruses (e.g., HSV, RSV, HCMV, and VZV) based
on in vitro experiments (241, 242). Clinical evidence suggests that
10% docosanol topical cream is safe and effective to reduce the
healing time and duration of symptoms for the treatment of re-
current herpes labialis caused by HSV-1 or HSV-2 infections
(241). Although its mechanism of drug action is still debated
(243), docosanol is believed to prevent virus entry by interfering
with the interaction between epithelial cell membrane receptors
and HSV envelope proteins (242, 244). Approved by the FDA in
July 2000, docosanol remains the only over-the-counter medica-
tion in clinical use for cold sores and fever blisters.
ACYCLIC GUANOSINE ANALOGUES
In the drug group of acyclic guanosine analogues, there are six
approved compounds: acyclovir, ganciclovir, valacyclovir (also
known as valaciclovir), valganciclovir, penciclovir, and famciclo-
vir (Fig. 11 and Table 2). Historically, acyclovir [9-((2-hydroxye-
thoxy)methyl)guanine] was first mentioned in a laboratory note-
book of Nick Oliver in 1974 (245). Its antiviral properties were
first uncovered by Peter Collins and John Bauer at the Wellcome
Laboratories in Beckenham, United Kingdom. Acyclovir was orig-
inally designed as an inhibitor of adenosine deaminases to en-
hance the antiviral activity of vidarabine (246). Elion et al. (247)
first pointed out that acyclovir owed its selectivity against HSV
to specific phosphorylation by viral thymidine kinases. A few
months later, acyclovir was reported to show potent activity
against herpesviruses (HSV-1 and HSV-2) (248). This certainly
was more of a surprise for a guanosine analogue (viz., acyclovir)
than for a 5-substituted 2=-deoxyuridine (viz., BVDU). Acyclovir,
targeting the viral DNA polymerase, was proven to be particularly
active against HSV-1 and HSV-2 but much less so against VZV
(249). Of the various acyclic guanosine analogues discovered sub-
sequently, penciclovir was pursued for VZV infections, and gan-
ciclovir became the drug of choice against HCMV infections (91).
In clinical practice, ganciclovir is being gradually superseded by
valganciclovir to treat HCMV infections, because valganciclovir
seems to modestly improve hearing and developmental outcomes
in the long term (250).
To increase oral bioavailability, the prodrug strategy was ap-
plied to all three acyclic nucleoside analogues, leading to the de-
velopment of famciclovir, valacyclovir, and valganciclovir (245).
For instance, famciclovir is the prodrug (diacetyl 6-deoxypenci-
clovir) of penciclovir. Acyclovir, ganciclovir, and penciclovir act
in similar fashions and are all phosphorylated. Ganciclovir is spe-
cifically phosphorylated by host kinases (251), while acyclovir and
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penciclovir are phosphorylated by viral thymidine kinases (247,
252) (Fig. 11). After their phosphorylation, acyclovir, ganciclovir,
and penciclovir triphosphates individually compete with the nat-
ural substrate dGTP of viral DNA polymerases to inhibit viral
DNA synthesis.
As of today, acyclovir continues to be the gold standard for the
treatment of HSV infection. Despite the high efficacy of acyclovir,
the mortality rate of patients with herpes simplex encephalitis who
received acyclovir is14 to 19% (253). For patients treated with a
standard course of intravenous acyclovir, a follow-up treatment
with a 3-month course of valacyclovir is unlikely to provide added
benefits compared to placebo (253). Nevertheless, owing to its
FIG 11 Tertiary structures of HSV-1 thymidine kinase and chemical formulas of acyclic guanosine analogues and acyclic nucleoside phosphonate analogues. (A)
The HSV-1 thymidine kinase dimer in complex with acyclovir. Two units of thymidine kinase are shown in pink and orange, respectively. Acyclovir can be
phosphorylated by HSV thymidine kinase and cellular enzymes (249). (B to G) Chemical formulas of acyclovir, famciclovir, valacyclovir, ganciclovir, penciclovir,
and valganciclovir in the group of acyclic guanosine analogues. (H to K) Chemical formulas of cidofovir, adefovir, tenofovir, and tenofovir alafenamide in the
group of acyclic nucleoside phosphonate analogues.
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increased oral bioavailability, valacyclovir has superseded acyclo-
vir for the treatment of HSV or VZV infections (254). In a recent
study, an economic comparison between valacyclovir and valgan-
ciclovir was performed, suggesting that in the first year after renal
transplantation, valganciclovir was more cost-effective than vala-
cyclovir (255). On the other hand, famciclovir offers significant
benefits, such as cost-effective therapy and accelerated rates of
lesion resolution (256). For these reasons, famciclovir is now
widely used to treat HSV or VZV infections.
ACYCLIC NUCLEOSIDE PHOSPHONATE ANALOGUES
In the drug group of acyclic nucleoside phosphonate (ANP) ana-
logues, there are 10 FDA-approved (combination) drugs (Table 2).
The ANP analogues that inhibit the activity of viral DNA polymerases
come from the hybridization of (S)-DHPA [(S)-9-(2,3-dihydroxy-
propyl)adenine] with phosphonoacetic acid, thus generating (S)-
HPMPA [(S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine].
Historically, the broad-spectrum antiviral activity of (S)-DHPA
was first reported by De Clercq et al. (257), shortly after acyclovir
had been described as a specific antiherpetic agent (248). In 1986,
(S)-HPMPA was first reported as a new broad-spectrum anti-
DNA virus agent by De Clercq et al. (258). Although (S)-HPMPA
itself was not commercialized for clinical use, it could be consid-
ered the prototype ANP, from which emanated a series of ANP
analogues, such as adefovir {PMEA [9-(2-phosphonomethoxy-
ethyl)adenine]}, cidofovir {(S)-HPMPC [(S)-1-(3-hydroxy-2-
phosphonomethoxypropyl)-cytosine]}, and tenofovir {(R)-
PMPA [(R)-9-(2-phosphonomethoxypropyl)adenine]} (219, 259,
260) (Fig. 11). In June 1996, cidofovir was approved for the treat-
ment of HCMV retinitis in AIDS patients (Table 2). Cidofovir has
also been used as an off-label drug to treat many DNA virus infec-
tions such as HSV and adeno-, pox-, polyoma-, and papillomavi-
rus infections (261). Later, adefovir was marketed in its oral pro-
drug form, adefovir dipivoxil (Hepsera), for the treatment of HBV
infection, as was tenofovir, in its prodrug form, TDF (Viread), for
the treatment of HIV and/or HBV infections.
In comparison to many TDF-based HIV therapies (Truvada,
Atripla, Complera, and Stribild), recent clinical trials indicate that
TDF monotherapy seems safe and effective against HBV infec-
tions (262–266). In comparisons of the effectiveness of TDF
monotherapy versus dual therapies, it has been shown that TDF
monotherapy is comparable to therapy with TDF plus ()FTC
(263, 267) or TDF plus ETV (268, 269), but it is less potent than
TDF plus pegylated interferon alfa 2a (270). Because of its potency
and high barrier to resistance, TDF monotherapy is currently rec-
ommended as the first-line treatment against chronic hepatitis B
according to American Association for the Study of Liver Diseases
(AASLD) guidelines (271), European Association for the Study of
the Liver (EASL) guidelines (272), and WHO guidelines (114). As
of April 2016, there has been no FDA-approved combination drug
for HBV infections. Therefore, the optimal combination drug that
achieves a sustained loss of serum hepatitis B virus surface antigen
has yet to be discovered.
The concept for all ANPs is the same: it is based on the presence
of a phosphonate (PCO) linkage (Fig. 11) instead of a normal
phosphate (POC) linkage, which is a characteristic of nucleotide
analogues against the activity of viral polymerases (273). The PCO
linkage, in contrast with the POC linkage, cannot be cleaved by
the hydrolase enzyme esterase. This fact explains the stability of
the ANPs, as chain terminators, after their incorporation into the
DNA chain (274). In the presence of the phosphonate group,
ANPs can no longer be removed from the DNA chain, thereby
leading to irreversible chain termination (259). Particularly, ANPs
need to first be phosphorylated (by cellular enzymes) to become
the diphosphate (not the triphosphate, as their phosphonate
group mimics the 5=-monophosphate in the nucleotides). The
following ANPs are, at present, on the market: (i) cidofovir (Vis-
tide) (now generic), (ii) adefovir dipivoxil (Hepsera), (iii) TDF
(Viread), (iv) TDF in combination with ()FTC (Truvada), (v)
TDF and ()FTC in combination with efavirenz (Atripla), (vi)
TDF and ()FTC in combination with rilpivirine (Complera
[United States] and Eviplera [European Union]), and (vii) TDF
and ()FTC in combination with elvitegravir and cobicistat
(Stribild). It is worth mentioning that cidofovir may be replaced
by its oral prodrug brincidofovir (originally referred to as hexade-
cyloxypropyl [HDP]-cidofovir) or CMX001 (193). Moreover,
Viread has been approved for the treatment of HIV and/or HBV
infections (Table 2). Truvada has been licensed for both therapy
and prophylaxis of HIV infections. As for the combination drug
Stribild, phase 3 clinical trials suggest that 90% of treatment-
naive HIV-infected patients receiving Stribild may have virologi-
cal success at 48 weeks (275). Moreover, Stribild is well tolerated in
virologically suppressed adults infected with HIV-1 (276).
In November 2015, TAF (GS-7340) was approved in combina-
tion with cobicistat, emtricitabine, and elvitegravir (Genvoya) to
treat HIV infections (Table 2). Genvoya is now on the market as a
fixed-dose combination of TAF (10 mg), cobicistat (150 mg),
emtricitabine (200 mg), and elvitegravir (150 mg). Three phase 3
clinical trials suggest that this combination drug could achieve
virological success in 1,732 (94.9%) of 1,825 patients at 48 weeks
of treatment (275, 277). Importantly, Genvoya provides a favor-
able safety profile because HIV-infected patients show fewer renal
and bone effects after receiving Genvoya (275, 277).
Approved by the FDA in 2016, TAFs are now used in combi-
nation with ()FTC (Descovy) or with ()FTC plus rilpivirine
(Odefsey) (Table 2). Forthcoming TAF-based drug combinations
include (i) TAF in combination with ()FTC plus efavirenz and
(ii) TAF in combination with ()FTC, elvitegravir, and cobicistat.
These drugs combined with TAF have distinct advantages because
they are specifically taken up by lymphocytes, and their dosages
can be reduced by10-fold (278, 279). This benefit thus signifi-
cantly reduces the risk of toxic effects such as kidney disturbances
and bone demineralization (278, 279).
HCV NS5A/NS5B INHIBITORS
As of April 2016, there are 8 approved (combination) drugs in the
group of HCV NS5A/NS5B inhibitors (Table 2). DAAs (direct-
acting antivirals) for the treatment of HCV infections encompass,
in principle, four classes: (i) NS3/4A protease inhibitors (Fig. 8),
(ii) NS5A protein inhibitors (Fig. 12), (iii) NS5B polymerase in-
hibitors (Fig. 13) of the nucleoside/nucleotide type, and (iv) NS5B
polymerase inhibitors of the nonnucleoside type (280). DAAs are
now replacing the combination of pegylated interferons and riba-
virin, the standard of care (SOC) for treating chronic HCV infec-
tions before 2013 (281).
HCV NS5A Inhibitors
As of April 2016, there are four approved NS5A inhibitors: dacla-
tasvir, ledipasvir, ombitasvir, and elbasvir (Table 2). As illustrated
in Fig. 12, daclatasvir can specifically bind to the HCV nonstruc-
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FIG 12 Tertiary structures of the HCV NS5A protein and chemical formulas of HCV NS5A inhibitors. (A) Tertiary structure of the HCV NS5A dimer in complex
with daclatasvir. Two units of the HCV NS5A dimer are shown in pink and orange, respectively (PDB data were reported in reference 282). (B to F) Chemical
formulas of ledipasvir, daclatasvir, ombitasvir, velpatasvir, and elbasvir in the group of HCV NS5A inhibitors. Note that velpatasvir is an experimental inhibitor
currently in phase 3 clinical trials.
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tural protein NS5A (282). The exact mechanisms of HCV NS5A
drug action remain debated, especially regarding their potential
inhibition of the structural stability, dimerization, or subcellular
distribution of NS5A (283, 284). Nevertheless, NS5A inhibitors
can block HCV RNA replication by interrupting the formation of
the membranous web, a heterogeneous meshwork within cyto-
plasmic membranous factories where HCV replication takes place
(284). Daclatasvir (Fig. 12) in combination with the protease in-
hibitor asunaprevir (Fig. 8) was approved in Japan, whereas the
FDA has not yet granted its approval as of April 2016.
Recent clinical trials have demonstrated the effectiveness of da-
clatasvir plus asunaprevir. The phase 3 HALLMARK-DUAL trial
enrolled patients with HCV genotype 1b infection, including 307
treatment-naive patients; 205 nonresponders; and 235 ineligible,
intolerant, or ineligible and intolerant patients (285). The treat-
ment outcome was measured by the rate of sustained virologic
response at 12 weeks (SVR12). This study reported promising
SVR12 rates (80%) for daclatasvir (60 mg, once daily) plus asu-
naprevir (100 mg, twice daily) in the three patient groups men-
tioned above (285). A phase 3 clinical trial that enrolled 135 inter-
feron-ineligible/intolerant patients and 87 nonresponder patients
showed high SVR12 rates (88%) for daclatasvir plus asunaprevir
in the treatment of chronic HCV genotype 1b infection (286).
Another clinical trial, which enrolled 230 patients with HCV ge-
notype 1b infection, demonstrated that the efficacy-and-safety
profile of daclatasvir plus asunaprevir was superior to that of tel-
aprevir plus peginterferon plus ribavirin (287). Overall, given the
1,000 patients with HCV genotype 1b infection in the clinical trials
mentioned above, treatment with daclatasvir (60 mg, once daily)
plus asunaprevir (100 mg, twice daily) reached a high rate of
SVR12 of up to 86.4% (n  864). A phase 4 trial is currently
ongoing to investigate the safety and efficacy of daclatasvir plus
asunaprevir in patients with chronic hepatitis C infection and
chronic renal failure (ClinicalTrials.gov registration number
NCT02580474). Results of this clinical trial are to be released in
2017.
In January 2016, the once-daily fixed-dose combination of el-
basvir plus grazoprevir (Zepatier) was approved by the FDA to
treat HCV genotype 1 or 4 infection (Table 2). Elbasvir and gra-
zoprevir inhibit HCV nonstructural protein NS5A (Fig. 12) and
NS3/4A protease (Fig. 8), respectively. A number of clinical trials
have been carried out to study the combination of grazoprevir
plus elbasvir: (i) the phase 2 C-WORTHY trial, which enrolled 253
patients with HCV genotype 1 infection, showed high rates of
sustained virologic response with treatment with grazoprevir plus
elbasvir at 12 and 18 weeks in both treatment-naive patients with
cirrhosis and patients with a previous null response to
PegIFN-2a plus ribavirin with or without cirrhosis (288); (ii) the
phase 3 C-SURFER trial, which enrolled 224 patients with HCV
genotype 1 infection and stage 4 to 5 chronic kidney diseases,
suggested that treatment with grazoprevir plus elbasvir caused a
low rate of adverse events and showed promising SVR12 rates
(289); and (iii) the phase 3 C-EDGE trial demonstrated that gra-
zoprevir plus elbasvir achieved high rates of SVR12 in 421 treat-
FIG 13 Tertiary structures of HCV NS5B polymerase and chemical formulas of HCV NS5B inhibitors. (A) Tertiary structure of HCV NS5B polymerase in
complex with dsDNA, beclabuvir, and sofosbuvir diphosphate (PDB accession numbers 4NLD and 4WTG). Note that beclabuvir and sofosbuvir diphosphate
bind to the allosteric site and the catalytic site of the HCV NS5B polymerase, respectively. (B to D) Chemical formulas of beclabuvir, dasabuvir, and sofosbuvir
in the group of HCV NS5B inhibitors. Note that beclabuvir is a forthcoming inhibitor in the combination drug of daclatasvir plus asunaprevir plus beclabuvir
in phase 4 clinical trials.
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ment-naive and noncirrhotic patients infected with HCV geno-
type 1, 4, or 6 (290). In these clinical trials, common side effects
such as headache, nausea, and fatigue were recorded (289, 290).
Given the 484 patients infected with HCV genotype 1 or 4 in three
clinical trials (C-WORTHY, C-SURFER, and C-EDGE), the com-
bination of grazoprevir (100 mg) plus elbasvir (50 mg) showed a
success rate of SVR12 of up to 95.8% (n  464). However, the
efficacy of grazoprevir plus elbasvir in HCV genotype 6 infection
has yet to be clarified, because the C-EDGE study showed SVR12
for only 8 out of 10 patients (290). Overall, the combination of
grazoprevir (100 mg) plus elbasvir (50 mg) has been shown to be
an effective pangenotypic drug (Zepatier) against HCV genotype
1 or 4 infection.
HCV NS5B Inhibitors
For the “nonnucleoside” NS5B polymerase inhibitors (Fig. 13),
sofosbuvir and dasabuvir have been approved by the FDA (Table
2), while a number of experimental inhibitors (i.e., deleobuvir,
setrobuvir, beclabuvir, and tegobuvir) have been identified to tar-
get allosteric sites of the HCV NS5B polymerase (178, 179). The
list of “nucleoside” NS5B polymerase inhibitors is so short be-
cause several compounds were discontinued prematurely due to
undesirable side effects. Sofosbuvir is, however, an exception in
this group, which did not reveal toxicity or drug resistance, and it
could be administered with other HCV drugs in combination as a
single oral pill for a total duration of 12 weeks, guaranteeing a high
level of sustained virologic response (291). To pursue interferon-
free treatment, sofosbuvir could be combined with an NS5A in-
hibitor, such as ledipasvir (292). This combination has been
dubbed Harvoni, which is administered as a once-daily oral pill
containing sofosbuvir (400 mg) and ledipasvir (90 mg). With this
combination, the treatment duration could eventually be short-
ened to12 weeks (293), providing high rates of sustained viro-
logic response in patients coinfected with HIV-1 and HCV geno-
type 1 or 4 (294).
To obtain clearance, a real “cure” of a chronic virus infection, as
noted for HCV, is unheard of in the medical history of infectious
diseases and sharply contrasts with the situation for HIV and HBV
infections. In principle, current development of anti-HIV drugs
requires lifelong treatments, while anti-HBV therapies may lead to
a real cure only in a small percentage of HBV-infected patients
(295, 296).
INFLUENZA VIRUS INHIBITORS
As of April 2016, 8 drugs have been approved to treat influenza
infections (Table 2). As illustrated in Fig. 14, these drugs could be
recognized as matrix 2 inhibitors (amantadine and rimantadine),
neuraminidase inhibitors (zanamivir, oseltamivir, peramivir, and
laninamivir octanoate), and polymerase inhibitors (ribavirin and
favipiravir). We describe the details of these drugs below.
Amantadine and Rimantadine
Amantadine (1-adamantanamine) was the first antiviral com-
pound approved in 1966 to treat influenza A virus infections
(297). This compound blocks the transport of H ions through
the M2 (matrix 2) protein channels (Fig. 14) into the interior of
viral particles, thus preventing the uncoating of influenza virus
particles within the endosomes (298, 299) (Fig. 4). After the dis-
covery of amantadine, rimantadine and a number of amantadine
derivatives were later synthesized (300, 301), but they did not
reach the market, except for amantadine and rimantadine. De-
spite their approval for adult patients, amantadine and rimanta-
dine do not contribute to the prevention, treatment, or reduced
duration of influenza A virus infection in children and the elderly
(302). Because of widespread resistance, amantadine has virtually
been abandoned in the treatment of influenza infections (303).
However, there is growing interest for the use of amantadine in the
early symptomatic treatment of Parkinson disease and levodopa-
induced dyskinesia (304, 305). More clinical evidence is required
to prove this new application of amantadine.
Zanamivir, Oseltamivir, Peramivir, and Laninamivir
Octanoate
The rational computer-aided design of zanamivir (306) marked a
new era in antiviral drug development (300). As a highly selective
inhibitor of influenza A and B virus neuraminidases (Fig. 14),
zanamivir prevents influenza infections by impeding virus release
rather than virus entry or other viral stages during the viral life
cycle (307) (Fig. 4). Zanamivir administered by inhalation was
soon joined by oseltamivir, which could be administered by the
oral route (308). Oral oseltamivir and inhaled zanamivir can offer
net benefits by reducing mortality and the duration of influenza
symptoms and complications, according to a systematic review
and meta-analysis of 74 observational studies (309). Soon after the
success of zanamivir and oseltamivir, two neuraminidase inhibi-
tors were later launched for the treatment of influenza infections
(310): peramivir, which could be given as a single intravenous
injection (311), and laninamivir octanoate, which would be effec-
tive if given as a single inhalation (312). Notably, peramivir has
clinical efficacy similar to that of oseltamivir in the treatment of
severe seasonal influenza (313), while the potency of laninamivir
octanoate has been shown for the treatment of seasonal influenza,
including oseltamivir-resistant virus, in adults (312). Intravenous
peramivir and inhalational laninamivir are used as a single-dose
treatments for influenza A and B viruses, but this application is
limited in a few countries (laninamivir in Japan and peramivir in
the United States, Japan, South Korea, and China) (314).
Ribavirin
Ribavirin (Virazole), 1-	-D-ribofuranosyl-1,2,4-triazole-3-car-
boxamide, is the first synthetic nucleoside analogue that has ever
been reported to be active against a broad spectrum of RNA vi-
ruses (HCV, RSV, and influenza virus): “its antiviral spectrum was
the broadest ever reported for a synthetic material that did not
induce interferon” (315). Its principal mechanism of drug action,
established shortly after the discovery of ribavirin (316), is the
inhibition of inosine-5=-monophosphate (IMP) dehydrogenase,
which converts IMP to xanthosine monophosphate (XMP) and
thus accounts for the de novo biosynthesis of GTP (317). The
inhibitory activity of ribavirin on the IMP dehydrogenase may
contribute to the immunosuppressive effects of ribavirin (318).
This in turn contributes to the significant success obtained by
ribavirin, in combination with peginterferon alfa 2a, for the treat-
ment of HCV infection (319, 320). HCV-infected patients who
received treatments of telaprevir, peginterferon alfa 2a, and riba-
virin had a significant level of sustained virologic response (321).
Approved for influenza treatment, ribavirin in the triphosphate
form efficiently inhibits the RNA polymerase of influenza virus
(322). Besides, ribavirin is used in the therapy of some hemor-
rhagic fever virus infections (e.g., Lassa fever [323]), but ribavirin
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FIG 14 Tertiary structures of influenza virus proteins (matrix 2, neuraminidase, and RNA polymerase) and chemical formulas of influenza virus inhibitors. (A)
Tertiary structure of the influenza A virus matrix 2 protein in complex with amantadine (PDB accession number 2KAD). Movies that simulate the binding of
approved antiviral drugs to viral or host proteins are available online (see http://www.virusface.com/). (B) Structure of influenza A virus neuraminidase in
complex with zanamivir (PDB accession number 2HTQ). (C) Tertiary structure of influenza virus RNA polymerase in complex with RNA. The RNA polymerases
of influenza A virus (left) (PDB accession number 3J9B) and influenza B virus (right) (PDB accession number 4WRT) are illustrated. The PA, PB1, and PB2
subunits of RNA polymerase (see structural details in reference 480) are shown in pink, orange, and gray, respectively. Ribavirin triphosphate targets the catalytic
site of the RNA polymerase to inhibit viral replication. Note that the RNA polymerase of influenza A virus is a tetramer (480), but the complete tetramer structure
of influenza virus RNA polymerase in complex with its inhibitors is still lacking. (D and E) Chemical formulas of amantadine and rimantadine, which target the
matrix 2 protein of influenza virus. (F and G) Chemical formulas of ribavirin and favipiravir, which target the viral RNA polymerase of influenza virus. (H to K)
Chemical formulas of zanamivir, laninamivir, peramivir, and oseltamivir, which target the viral neuraminidase of influenza virus.
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has never been formally licensed for this medication. The poten-
tial activity of ribavirin against RNA viruses has also been shown
in the search for antiviral candidates against many emerging in-
fectious diseases such as dengue virus (324), norovirus (325, 326),
Marburg virus (MARV) (327), and Hendra and Nipah viruses
(328). Nevertheless, more clinical evidence is still required to
prove these new applications.
Favipiravir
Favipiravir (also known as T-705), 6-fluoro-3-hydroxy-2-pyraz-
ine carboxamide (Fig. 14), has been primarily pursued for the
treatment of influenza infections (329–331). Approved in Japan,
favipiravir can be used in the treatment of influenza A, B, and C
virus infections (Table 2). According to the mechanism of drug
action postulated by Furuta et al. (332), favipiravir is converted
intracellularly to its ribofuranosyl monophosphate form by the
phosphoribosyl transferase; two phosphorylations subse-
quently convert the ribofuranosyl monophosphate form to the
triphosphate form, the active metabolite of favipiravir. Impor-
tantly, favipiravir triphosphate shows broad-spectrum inhibi-
tory activities against the RNA polymerases of influenza A vi-
ruses (including the highly pathogenic H5N1 viruses) (330,
333) and many other positive-sense RNA and negative-sense
RNA viruses (331). Recently, favipiravir has been proposed to
treat patients infected with Ebola virus (EBOV) (334). Prelim-
inary results suggest that favipiravir efficiently inhibits Ebola
virus infections in mouse models (335, 336), but further inves-
tigations are still needed (337). In addition, favipiravir can
inhibit the replication of human norovirus (325, 326) and hu-
man arenaviruses (Junin, Machupo, and Pichinde viruses)
(338, 339), but these new applications require further evidence
from clinical trials.
INTERFERONS, IMMUNOSTIMULATORS,
OLIGONUCLEOTIDES, AND ANTIMITOTIC INHIBITORS
In the drug group of interferons, immunostimulators, oligonucle-
otides, and antimitotic inhibitors, there are 8 FDA-approved
drugs: (i) interferons for HBV and/or HCV infections; (ii) fomi-
virsen (an antisense oligonucleotide) for HCMV infections; and
(iii) podofilox (an antimitotic inhibitor), imiquimod (an immu-
nostimulator), and sinecatechins (a botanical drug) for the treat-
ment of external genital warts caused by HPV infections (Table 2).
These approved drugs share one thing in common: they exert
specific inhibitory effects without targeting viral proteins directly.
Below, we describe the details of these drugs.
Interferons
To treat HBV or HCV infections, three interferons have been li-
censed: interferon alfacon 1, pegylated interferon alfa 2a
(PegIFN-2a), and PegIFN-2b (Table 2). Due to its severe ad-
verse events, interferon alfacon 1 has been discontinued since Sep-
tember 2013. Currently, PegIFN-based regimens are preferably
used for HBV but not for HCV infections, because interferon-free
drugs are now effective against HCV infections (340). Interferon
alpha (IFN), predominantly secreted by hematopoietic cells
(e.g., plasmacytoid dendritic cells), is a well-defined type I inter-
feron that stimulates the immune system for antiviral defense
(341–343). To increase the half-life of interferon inhibitors in se-
rum, polyethylene glycol polymers are covalently attached to
IFN- for the production of PegIFN. Interestingly, there is only
one amino acid at position 23 that distinguishes human IFN-2a
(hIFN-2a) from hIFN-2b (K23 in hIFN-2a and R23 in
hIFN-2b) (Fig. 15). Regarding the mechanism of drug action,
PegIFN-2a and PegIFN-2b mainly interfere with viral replica-
tion in two aspects. First, they stimulate immunity cells (CD8
cells and natural killer T cells) to enhance the noncytolytic clear-
ance of viruses by cytokines or cytolysis of infected cells (344).
Second, they stimulate the expression of innate antiviral genes and
proteins (e.g., APOBEC3A/B and MxA) to block viral replication
(344).
In clinical practice, interferon-based treatments are infre-
quently used due to their multiple side effects, high costs, and
inconvenience of administration (345). Importantly, a wide range
of side effects with PegIFN have been reported: fever, fatigue,
bone marrow suppression, influenza-like symptoms, depres-
sion, and exacerbation or development of autoimmune ill-
nesses (346). For this reason, PegIFN-2a has been approved
only for HBV-infected adults (180 
g/week for 48 weeks) but not
for children (114, 271). Moreover, it remains debatable whether
interferons should or should not be combined with other antiviral
compounds (e.g., lamivudine, adefovir dipivoxil, TDF, or enteca-
vir) (347–349). For instance, PegIFN-2a plus adefovir dipivoxil
may increase HBV-specific T cell restoration (349), whereas
PegIFN-2a with TDF-based therapies at 48 weeks does not in-
crease the seroconversion rate of HBeAg-positive patients coin-
fected with HBV and HIV (350). Furthermore, PegIFN-2a
should not be used with telbivudine due to an increased risk of
peripheral neuropathy (351). The added value of interferons in
combination with nucleos(t)ide analogues warrants further inves-
tigation.
Immunostimulatory and Antimitotic Inhibitors
Approved by the FDA in February 1997, 5% imiquimod cream
(Aldara) is a patient-applied immune response modifier for
the treatment of external genital warts caused by HPV infections
(352, 353). Imiquimod, 1-isobutyl-1H-imidazo[4,5-c]quinolin-
4-amine (also known as R-837 and S-26308), is a nonnucleoside
heterocyclic amine (Fig. 15). Although its antiviral activity could
not be shown by in vitro experiments, imiquimod stimulates
macrophages to secrete cytokines (e.g., interferon alpha, tumor
necrosis factor alpha [TNF-], interleukin-1 [IL-1], IL-6, and
IL-8) for wart regression and local inflammatory reactions
(352, 354). Clinical trials suggested that 5% imiquimod cream
was safe and well tolerated in the treatment of external genital
warts (352, 353, 355). Moreover, it is applied 3 times per week
until complete clearance is achieved or for a maximum of 16
weeks, and the most common side effects are skin reactions
(e.g., itching, burning, and erythema). Clearance rates with 5%
imiquimod cream vary from 37% to 50%, and the recurrence
rate is 13% (356).
A 15% sinecatechin ointment (Veregen) is the first FDA-ap-
proved botanical drug for the topical treatment of external genital
warts (357). The name sinecatechins originates from the Latin
name for Chinese green tea (Camellia sinensis) and its major
chemical components (catechins) (357). Veregen is a purified
product of catechins from leaves of Chinese green tea containing
80% catechins and polyphenols. Importantly, catechins (Fig.
15) are known for their antiangiogenic activity, anti-inflamma-
tory and immunostimulatory activities, and antimicrobial poten-
tial (358). Two phase 3 clinical studies suggest that 15% sinecat-
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echin ointment is a well-tolerated, self-applicable, and effective
topical treatment to clear external genital warts (359, 360). The
most common side effects with sinecatechins are local skin and
application site reactions (e.g., erythema, pruritus, burning, pain,
and erosion). The clearance rate with 15% sinecatechin ointment
reaches54%, and the recurrence rate is7% at 12 weeks (356).
Podofilox (Condylox) is an antimitotic compound purified
from crude podophyllum resin within the roots and rhizomes of
May apple or podophyllum plant (either North American Podo-
phyllum peltatum or Indian Podophyllum emodi) (361). Podofilox
is safe and effective in the treatment of external genital warts but
not mucous membrane warts (361, 362). Instead of targeting HPV
proteins directly, podofilox is a cytotoxic drug with specific phar-
macological actions against the formation of the mitotic spindle at
metaphase, leading to the interruption of cell division (362, 363).
Two topical treatments are currently approved for self-applicable
administration: a 0.5% podofilox solution and a 0.5% podofilox
gel. In particular, podofilox is applied when the areas of external
warts are 10 cm2. The internal use of podofilox in either the
vagina or the anus is not recommended. The most common side
effects with podofilox are inflammation, burning, erosion, pain,
or itching (364). Clearance rates with the 0.5% podofilox solution
vary from 45% to 77%, and the recurrence rates are between 4%
and 33% (356).
FIG 15 Tertiary structures of interferons and chemical formulas of podofilox, imiquimod, and catechin. (A and B) Cartoon representations of interferon alfa 2a
(PDB accession number 4YPG) and interferon alfa 2b (PDB accession number 1RH2). Sequence comparison suggests that amino acid K23 in interferon alfa 2a
and amino acid R23 in interferon alfa 2b mark the only sequence difference between interferon alfa 2a and interferon alfa 2b. Structural movies are available
online (http://www.virusface.com/). (C to E) Chemical formulas of podofilox, imiquimod, and catechin. Note that catechin is the major ingredient of the
botanical drug sinecatechin.
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Antisense Oligonucleotides
Fomivirsen (Vitravene) is the first FDA-approved antisense oligo-
nucleotide harboring a 21-nucleotide phosphorothioate oligonu-
cleotide (5=-GCG TTT GCT CTT CTT CTT GCG-3=) (365). Based
on its antisense mechanism, fomivirsen is complementary to a
sequence in mRNA encoding major immediate early region 2 of
HCMV; thus, the binding of fomivirsen to this region inhibits the
gene expression of essential HCMV proteins (366). Fomivirsen
sodium, administered as an intravitreal injection into human eyes,
has been approved for treating HCMV retinitis in patients in-
fected with AIDS (367). Despite the fact that it is well tolerated and
has a favorable safety profile (368), intravitreous fomivirsen has
been discontinued for commercial reasons.
FORTHCOMING ANTIVIRAL INHIBITORS
In addition to the 90 approved antiviral drugs, many experimental
inhibitors have been under investigation in phase 3 clinical trials
(http://www.clinicaltrials.gov/). For instance, besifovir is an HBV
inhibitor showing an efficacy similar to that of the approved in-
hibitor entecavir (369), but its safety is worrying (370). As the first
thiazolide in clinical trials, nitazoxanide may inhibit chronic HCV
(371), whereas more randomized clinical trials with a low risk of bias
are still needed (372). Development of many antiviral inhibitors still
depends on the results of phase 3 trials, such as human monoclonal
antibody REGN2222 against RSV (373) (ClinicalTrials.gov registra-
tion number NCT02325791), the HIV NNRTI doravirine (374) (reg-
istration number NCT02397096), and the HIV integrase inhibitor
GS-9883 (registration numbers NCT02607930, NCT02607956,
NCT02603120, and NCT02603107). Here, we provide an overview of
four forthcoming antiviral drugs: (i) sofosbuvir plus velpatasvir for
treatment of infections by HCV genotypes 1 to 6, (ii) daclatasvir plus
asunaprevir with or without beclabuvir for treatment of HCV geno-
type 1 infections, (iii) FV100 for treatment of VZV infections, and (iv)
letermovir for treatment of HCMV infections (Table 3).
Sofosbuvir plus Velpatasvir
The combination of sofosbuvir (400 mg) plus velpatasvir (100
mg) has been recognized as an effective pangenotypic therapy
against infections by HCV genotypes 1 to 6 (375, 376). Sofosbuvir
is an approved nucleoside compound that inhibits HCV NS5B
polymerase activities (Fig. 13), while velpatasvir is an experimen-
tal inhibitor targeting HCV nonstructural protein NS5A (Fig. 12).
HCV pangenotypic drugs may require no genotyping tests and
potentially offer the simplest “test-and-cure” strategy to eliminate
HCV infections (375). Supported by successful clinical trials, the
once-daily fixed-dose combination of sofosbuvir plus velpatasvir
was submitted to the FDA as a new drug application on 28 Octo-
ber 2015.
A number of clinical trials have been carried out to study
the combination drug of sofosbuvir plus velpatasvir: (i) the
ASTRAL-1 trial, which enrolled 740 HCV-infected patients with
noncirrhotic or compensated cirrhosis, demonstrated the effec-
tiveness of the combination of sofosbuvir plus velpatasvir against
HCV genotype 1, 2, 4, 5, or 6 (377); (ii) the ASTRAL-2 and
ASTRAL-3 trials, which enrolled 266 and 552 patients, respec-
tively, suggested that therapy with sofosbuvir plus velpatasvir was
superior to therapy with sofosbuvir plus ribavirin for treatment of
infection by HCV genotype 2 or 3 (376); (iii) the ASTRAL-4 trial
further revealed that sofosbuvir plus velpatasvir achieved high
rates of SVR12 in 267 patients with HCV infection (genotypes 1 to
6) and decompensated cirrhosis (378); and (iv) two randomized
clinical trials, which enrolled 321 and 377 patients, respectively,
suggested that treatment with sofosbuvir (400 mg) plus velpatas-
vir (100 mg) provided remarkable rates of SVR12 in treatment-
naive or treatment-experienced patients infected with HCV geno-
types 1 to 6 (379, 380). The combination treatment in these
clinical trials gave rise to common side effects such as fatigue,
headache, insomnia, or nausea (376, 378–380). Nevertheless,
given the 1,254 patients infected with HCV genotypes 1 to 6 in the
six clinical trials described above, treatment with sofosbuvir (400
mg, once daily) plus velpatasvir (100 mg, once daily) showed a
success rate of SVR12 of up to 97.4% (n 1,221).
Daclatasvir plus Asunaprevir with or without Beclabuvir
To treat HCV genotype 1 or 4 infection, phase 3 clinical trials were
established to study (i) a fixed-dose combination of daclatasvir
(60 mg, once daily) plus asunaprevir (100 mg, twice daily) (285)
and (ii) a twice-daily fixed-dose combination of daclatasvir (30
mg) plus asunaprevir (200 mg) plus beclabuvir (75 mg) (381,
382). Daclatasvir is an FDA-approved inhibitor targeting HCV
NS5A (Fig. 12), and beclabuvir is an experimental inhibitor tar-
geting HCV NS5B (Fig. 13). The combination of the HCV pro-
tease inhibitor asunaprevir with daclatasvir was approved in Ja-
pan, but the FDA has not approved this combination as of April
2016.
The effectiveness of daclatasvir plus asunaprevir plus beclabuvir
has been demonstrated in recent clinical trials: (i) the phase 2
AI443014 trial, which enrolled 187 patients with HCV genotype 1
infection, revealed that the virologic response with daclatasvir
plus asunaprevir plus beclabuvir (75 mg) was higher than that
with daclatasvir plus asunaprevir plus beclabuvir (150 mg) (381);
(ii) the phase 3 UNITY-1 trial, which enrolled 312 treatment-
naive and 103 treatment-experienced noncirrhotic patients in-
fected with chronic HCV genotype 1, suggested that daclatasvir
plus asunaprevir plus beclabuvir achieved high rates (89%) of
SVR12 (382); and (iii) the phase 3 UNITY-2 trial, which enrolled
112 treatment-naive and 90 treatment-experienced patients in-
fected with chronic HCV genotype 1 and with compensated cir-
rhosis, suggested that daclatasvir plus asunaprevir plus beclabuvir
achieved promising rates (85%) of SVR12 (383). The most com-
mon side effects with this combination drug were headache, diar-
rhea, fatigue, and nausea (381, 382). Given the 597 patients with
HCV genotype 1 infection in the clinical trials described above,
treatment with daclatasvir (30 mg) plus asunaprevir (200 mg) plus
beclabuvir (75 mg) showed a success rate of SVR12 of up to 91.5%
(n 546).
FV100
FV100 (FV for FermaVir) has been developed as an effective, well-
tolerated, once-daily treatment for herpes zoster or shingles, a
painful rash caused by VZV infections (384). FV100 is a lipophilic
bicyclic nucleoside analogue (Fig. 5) that inhibits the activity of
the VZV DNA polymerase (385). In vitro experiments on VZV-
infected cells at day 3 postinfection demonstrated that FV100 ef-
ficiently inhibited VZV replication at a 50% effective concentra-
tion (EC50) of 0.09
M, which was more potent than BVDU (EC50
of 0.9
M) and acyclovir (EC50 of 9
M) (386).
A phase 1 study, which enrolled 107 VZV-infected patients
(384), concluded that once-daily oral dosing of FV100 could be
sufficient to maintain the drug concentration above the EC50 in
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vivo, and FV100 was well tolerated in elderly and young patients
(385, 387). A phase 2 clinical trial, which enrolled 329 patients
aged 50 years and older, evaluated the incidence of postherpetic
neuralgia (PHN) for treatment with FV100 versus valacyclovir at
90 days. The PHN incidence rates with 200 mg FV100 (17.8%;
19/107) and 400 mg FV100 (12.4%; 14/113) were lower than that
with 1,000 mg valacyclovir (20.2%; 22/109) (Contravir). To com-
pare 400 mg FV100 with 1,000 mg valacyclovir, results of a phase
3 trial recruiting 985 patients will be released by the end of 2016
(ClinicalTrials.gov registration number NCT02412917).
Letermovir
Letermovir (MK-8228 or AIC246) is a 3,4-dihydro-quinazoline-
4-yl-acetic acid derivative that targets the pUL56 subunit of the
HCMV terminase complex to block viral DNA processing and/or
packaging (388–390). Based on in vitro experiments, letermovir
showed promising antiviral activity in different cell lines in com-
parisons of letermovir (EC50 of 0.0035 to 0.0056 
M) versus gan-
ciclovir (EC50 of 0.32 to 2.39 
M) (391). The first proof-of-con-
cept trial, which enrolled 27 transplant recipients with active
HCMV infections, identified virus clearance in 6 of 12 patients
(50%) who received 14 days of letermovir, in comparison to 2 of 7
patients (28.6%) who received the local standard of care (67). A
phase 2 clinical trial, which enrolled 131 HCMV-seropositive al-
logeneic hematopoietic stem cell transplant recipients, demon-
strated that the incidence of HCMV infection in patients who
received once-daily doses of 240 mg letermovir (29%; 10/34) at 12
weeks was significantly lower than that in patients who received
placebo (64%; 21/33) (392). In this phase 2 clinical trial, the leter-
movir resistance mutation V236M was identified in patients who
failed treatment with a suboptimal letermovir concentration of 60
mg, but treatment with 240 mg letermovir at 12 weeks achieved
complete suppression of viremia (393).
Letermovir at 240 mg had significant anti-HCMV activity, with
an acceptable safety profile (392). Gastrointestinal disorders, in-
cluding diarrhea, nausea, and vomiting, were common side effects
in the phase 2 clinical trial (392). An ongoing phase 3 clinical trial,
enrolling about 540 HCMV-seropositive allogeneic hematopoi-
etic stem cell transplant recipients, will show the efficacy and
safety of 240 mg letermovir in preventing HCMV infections 24
weeks after transplant actions (ClinicalTrials.gov registration
number NCT02137772). Results of this clinical trial will be re-
leased in 2017.
ANTIVIRAL STRATEGIES AGAINST CURRENT AND EMERGING
INFECTIOUS DISEASES
Emerging viral infections (e.g., Zika virus, dengue virus, and Ebola
virus [EBOV]) are afflicting millions of humans worldwide. For
this reason, there is growing interest in developing new treatments
against emerging infectious diseases (394). Here, we highlight an-
tiviral strategies against 41 infectious diseases. For convenience,
we categorize these viruses into four groups: (i) viruses (n  4)
targeted by both approved vaccines and antiviral drugs, (ii) vi-
ruses (n  5) targeted by approved antiviral drugs but not by
vaccines, (iii) viruses (n 13) targeted by approved vaccines but
not by antiviral drugs, and (iv) viruses (n 19) targeted by neither
approved vaccines nor antiviral drugs.
Viruses Targeted by both Antiviral Drugs and Vaccines
As of April 2016, the FDA has approved vaccines and antiviral
drugs to treat HBV, HPV, VZV, and influenza viruses. In addition
to the antiviral drugs summarized above, here, we briefly describe
FDA-approved vaccines.
HBV vaccines. Three HBV vaccines (Pediarix, Engerix-B, and
Recombivax HB) have been approved for all HBV genotypes. The
effectiveness of universal HBV immunization in preventing
chronic hepatitis B infections is 90 to 95% (395). Due to the
success of HBV vaccines, the rate of global HBV vaccine coverage
is 75%, and this rate is much higher in developed countries
(89% in the United States and 91% in the Western Pacific) (395).
VZV vaccines. As two live-attenuated VZV vaccines, Zostavax
and Varivax were licensed against varicella in 1995 and against
herpes zoster in 2006, respectively (80). Herpes zoster vaccines can
efficiently protect older adults from herpes zoster diseases (396).
The mean effectiveness of a single dose of the varicella vaccine is
80 to 85% against all levels of disease severity (397).
HPV vaccines. Three vaccines have been approved for different
HPV types: Cervarix for HPV-16 and HPV-18, Gardasil 9 for
HPV-9, and Gardasil for HPV-6, HPV-11, HPV-16, and HPV-18.
Routine vaccination using either Gardasil or Cervarix is currently
recommended (398).
Influenza virus vaccines. The FDA has approved (i) monova-
lent vaccines for influenza A (influenza A [H5N1] virus monova-
lent vaccine and influenza A [H1N1] 2009 virus monovalent vac-
cines), (ii) trivalent vaccines for influenza A and B viruses (Afluria,
Agriflu, Fluad, Fluarix, Flublok, Flucelvax, FluLaval, Fluvirin, and
Fluzone), and (iii) quadrivalent vaccines for influenza A and B
viruses (FluMist, Fluarix, Fluzone, and FluLaval). Apart from
their important roles against viral infections, influenza vaccines
have their limitations (399, 400). First, after influenza vaccination,
it takes up to 2 weeks in adults and 6 weeks in children to develop
immunity. Patients might be vulnerable within this period. Sec-
ond, the effectiveness of influenza vaccination is impaired by
many factors (e.g., vaccine mismatch, immunosuppression, or
lack of compliance). Third, due to emerging influenza virus
strains, a new vaccine may not be available for periods of up to
several months, and not all patients could be vaccinated in a time
of need. Therefore, additional coverage by antiviral drugs (i.e.,
neuraminidase inhibitors) is still required. The significant varia-
tion of influenza virus strains may cause resistance to antiviral
agents; thereby, optimal antiviral treatments are yet to be discov-
ered (399, 401).
Viruses Targeted by Antiviral Drugs but Not by Vaccines
As of April 2016, the FDA has approved antiviral drugs for the
treatment of HIV, HCV, HSV, RSV, and HCMV, but their vac-
cines are still lacking: (i) HIV and HCV vaccines are not available
and will be unlikely to be available in the foreseeable future, so
treatments of these infections depend solely on effective antiviral
drugs that are currently available; (ii) although an effective HSV
vaccine is still lacking, many HSV vaccine candidates (e.g.,
HSV529) are currently being tested in clinical trials (402, 403);
(iii) there is no licensed vaccine for RSV, but a number of prom-
ising vaccine candidates (e.g., live-attenuated RSV vaccine MEDI-
559) are currently being evaluated in advanced clinical trials (404,
405); and (iv) most HCMV vaccines are produced by either atten-
uating HCMV to generate modified-virus vaccines or isolating
subunit viral antigens to generate individual-antigen vaccines
(406). Clinical trials are currently being undertaken to evaluate
promising candidates (e.g., AD169, Towne/Toledo chimeric vac-
cines, and DNA vaccines of gB and pp65) (406, 407). The devel-
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opment of HCMV vaccination still faces many challenges, such as
the clinical selection of appropriate trial endpoints and the iden-
tification of viral antigens with desirable features for vaccine de-
sign (408).
Viruses Targeted by Vaccines but Not by Antiviral Drugs
As of April 2016, approved vaccines are available for 13 infectious
diseases, but their antiviral drugs are still lacking. The list of ap-
proved vaccines could be summarized as follows: (i) human ade-
novirus vaccine (Adenovirus Type 4 and Type 7 Vaccine, Live,
Oral), (ii) rotavirus vaccines (Rotarix for rotavirus serotype G1,
G3, G4, or G9 and RotaTeq for rotavirus serotype G1, G2, G3, or
G4), (iii) hepatitis A virus vaccines (Havrix and Vaqta), (iv) po-
liovirus vaccines (Kinrix, Quadracel, and Ipol), (v) yellow fever
virus vaccine (YF-Vax), (vi) Japanese encephalitis virus vaccines
(Ixiaro and JE-Vax), (vii) measles vaccines (M-M-R II and Pro-
Quad), (viii) mumps vaccines (M-M-R II and ProQuad), (ix) ru-
bella vaccines (M-M-R II and ProQuad), (x) varicella vaccine
(ProQuad), (xi) rabies vaccines (Imovax and RabAvert), (xii) va-
riola virus (smallpox) vaccine (ACAM2000), and (xiii) hepatitis E
virus (HEV) vaccine (HEV239). HEV239 is the only HEV vaccine
that was approved in China in 2012 (409), while many vaccine
candidates are currently under examination in clinical trials (410).
In addition to the approved vaccines mentioned above, many
antiviral agents have been designed. As an approved drug against
HCMV, cidofovir can efficiently inhibit viral infections with hu-
man adenovirus, but clinical evidence is still lacking (411). Al-
though no antiviral compound is formally approved for HEV,
preliminary clinical observations suggest that pegylated interferon
and ribavirin alone might offer a sustained virological response,
but HEV clinical trials are still required (412). A number of prom-
ising compounds (e.g., hydantoin, guanidine hydrochloride, L-
buthionine sulfoximine, and Py-11) can inhibit viral replication of
picornavirus in vitro, but in vivo evidence from clinical trials is
largely lacking (413). As for rabies infections, they are generally
treatable by using postexposure prophylaxis with the administra-
tion of rabies immunoglobulin and vaccine (414). Postexposure
prophylaxis must be initiated soon after rabies exposures, mostly
through animal bites (415). For viral infections like polio, yellow
fever, and measles, adequate protection can be achieved by vacci-
nation in some circumstances, but the coverage of antiviral drugs
is currently not available.
Off-label drugs might be considered valuable options when li-
censed treatments are not available. For instance, cidofovir might
be an off-label prescription to treat various DNA virus infections
such as human polyomavirus, adenovirus, and smallpox (416).
Three drugs (foscarnet, ganciclovir, and cidofovir) approved for
HCMV can also inhibit the viral DNA polymerase of human her-
pesvirus 6 (HHV-6) (127). Despite this, the effectiveness of off-
label drugs is yet to be fully proven in clinical trials.
Viruses Targeted by neither Vaccines nor Antiviral Drugs
Apart from 22 well-known viruses targeted by vaccines and/or
antiviral drugs, a great number of emerging infectious diseases
without any licensed treatments are currently afflicting millions of
patients (417). Therefore, a great deal of attention has been paid to
many emerging viruses, such as Epstein-Barr virus (EBV) (418),
human parvovirus B19 (419, 420), human norovirus (421), hu-
man rhinovirus (422), human herpesvirus 6 (127), human coro-
navirus (423), human astrovirus (424), human sapovirus (425),
chikungunya virus (324), dengue virus (426), West Nile virus
(427), Hendra virus (328), Nipah virus (328), Ebola virus (428,
429), Marburg virus (MARV) (429), Lassa virus (430), Junin virus
(430), Machupo virus (431), and, most recently, Zika virus (432).
Here, we briefly discuss antiviral strategies against these emerging
infectious diseases.
dsDNA viruses: EBV, human polyomavirus, and herpesvirus
6. EBV, also called human herpesvirus 4, was first reported in
1964. Many antiviral drugs (e.g., valacyclovir, ganciclovir, and val-
ganciclovir) can actively inhibit EBV replication in vitro or in
small clinical trials, but large-scale clinical trials are still required
(418, 433). EBV vaccines have been generated based on the EBV
envelope glycoprotein GP350 and CD8 T cell peptide epitopes,
but their effectiveness requires further improvement (418).
Human polyomavirus was first discovered by Ludwik Gross in
1953 (434). The best-known types of human polyomaviruses are
JC and BK viruses, which infect80% of adult populations (435).
Recognized as promising drug candidates, human monoclonal
antibodies target viral protein 1 of JC virus to inhibit JC virus
infections, and they exert cross-reactivity against many JC virus
strains (436). Cidofovir might be an off-label drug to treat various
DNA virus infections (e.g., human polyomavirus) (416).
Human herpesvirus 6 was first isolated in patients with lym-
phoproliferative disorders in 1986 (437). There is no vaccine or
drug licensed for human herpesvirus 6, but one experimental
compound {(R)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine
(H2G)} and four drugs (ganciclovir, foscarnet, cidofovir, and
artesunate) approved for other clinical uses are under investiga-
tion (127).
ssDNA virus: human parvovirus B19. Human parvovirus B19,
discovered in 1975, is the best-known virus in the group of ssDNA
viruses. Most infections by human parvovirus B19 in immuno-
competent patients do not require any treatment, because the
symptoms are transient (420). Although controlled studies are
still required, intravenous immunoglobulin (IVIG) therapy has
been recognized as a popular alternative because it offers a good
source of neutralizing antibodies in immunocompromised pa-
tients exposed to human parvovirus B19 (419). Intravenous im-
munoglobulin therapy substantially increases reticulocyte counts
and hemoglobin levels, but 33.9% of treated patients may have a
relapse at a mean of 4.3 months (438). Apart from neutralizing
antibodies, a recent study suggests that cidofovir at 500
M could
significantly reduce virus infectivity in vitro, but clinical evidence
is still required (439).
Positive-sense ssRNA viruses: Zika virus, norovirus, corona-
virus, rhinovirus, astrovirus, sapovirus, dengue virus, chikun-
gunya virus, andWest Nile virus. Zika virus, discovered in 1947,
was first isolated in a monkey in the Zika forest of Uganda (440).
Since the first outbreak of Zika virus in the Yap Islands in 2007,
Zika virus transmissions have been reported in 64 countries ac-
cording to a WHO report on 13 April 2016 (http://www.who
.int/). Recent evidence suggests that 0.95% of Zika virus infec-
tions in pregnant women may lead to microcephaly (abnormally
small head) in infants (441). Zika virus infections are also associ-
ated with severe neurological complications such as Guillain-
Barré syndrome (440). Unfortunately, a vaccine, antiviral com-
pound, or good serological test is not available for Zika virus today
(442). Vaccine candidates are now under development, but a safe
and effective vaccine will probably take 3 to 10 years (443, 444).
Currently, the best prevention, especially for pregnant women
De Clercq and Li
730 cmr.asm.org July 2016 Volume 29 Number 3Clinical Microbiology Reviews
and infants, is to avoid mosquito exposure because Zika virus is
transmitted mainly by infected mosquitoes.
Human norovirus was first identified in stored human stool
samples in 1972. Virus-like particles containing norovirus geno-
type GI.1/GII.4 have been designed as vaccine candidates, and
their effectiveness seems promising in phase 1 clinical trials (421).
Many antiviral agents (e.g., EV71, ribavirin, and favipiravir) effi-
ciently inhibit norovirus protease or RNA polymerase, but their
development is still at an early stage (325, 326).
Human coronavirus, discovered in the 1960s, is known to
cause severe acute respiratory syndrome (SARS) and Middle East
respiratory syndrome (MERS) (423). Many antiviral candidates
(e.g., corticosteroids) potentially inhibit human coronavirus, and
more details have been elucidated in recent review articles (445–
447).
Human rhinovirus, first discovered in the 1950s, is the most
common cause of upper respiratory tract infections (422). There
is no vaccine or drug licensed for human rhinovirus, but a number
of antiviral agents (e.g., pleconaril, vapendavir, and pirodavir)
have been under investigation (422). However, it remains a chal-
lenge to develop rhinovirus drugs and vaccines, because the rhi-
novirus genome, classified into100 serotypes, is highly variable
(422).
Dengue, chikungunya, and West Nile viruses from the family
Flaviviridae are mosquito-borne viruses that pose significant risks
to human health throughout the world (448, 449). Dengue virus,
discovered in the 1960s, is the cause of several pandemics (426).
Many experimental inhibitors (e.g., sinefungin, SDM25N, and
CCG-3394) have been designed to target the NS4B and NS5 pro-
teins of dengue virus (450, 451). Although a number of vaccine
candidates (e.g., CYD-TDV and TDEN) have reached advanced
clinical trials (452, 453), it remains a challenge to develop dengue
virus vaccines with optimal efficacy against all 4 dengue virus se-
rotypes. As for the treatment of chikungunya virus, many antiviral
drugs (ribavirin and pegylated interferon alfa) and experimental
agents (e.g., chloroquine, arbidol, and chlorpromazine) may in-
terfere with different stages of the virus life cycle (324), but clinical
evidence is largely lacking. Regarding the treatment of West Nile
virus, veterinary vaccines have been licensed for use in horses and
dogs (454, 455). Nevertheless, vaccine candidates (454, 455) and
small-molecule inhibitors (456, 457) against human West Nile
virus are still under investigation.
Human astrovirus (424) and sapovirus (425) were first discov-
ered in human diarrheic stool samples in 1975 and 1976, respec-
tively. Astrovirus and sapovirus infections cause acute gastroen-
teritis in humans and animals (424, 425). Due to the lack of
commercial interest, the development of vaccines and antiviral
agents against human astrovirus and sapovirus is rather slow.
However, improved sanitation and hygiene can efficiently prevent
viral infections, because astrovirus and sapovirus are transmitted
primarily through the fecal-oral route (424, 425).
Negative-sense ssRNA viruses: Ebola, Marburg, Hendra,
Nipah, Lassa, Junin, and Machupo viruses. Ebola and Marburg
viruses from the family Filoviridae were first discovered in 1976
and 1967, respectively. Both zoonotic viruses were originally
transmitted from bats to humans (458). As of April 2016, there is
no vaccine or antiviral drug licensed for EBOV and MARV. Phase
1/2 clinical trials have been undertaken to prove the effectiveness
of treatment candidates such as favipiravir, EBOV glycoprotein
vaccine (EBOVGP), and ZMapp (334, 428, 459). Moreover, con-
valescent-phase plasma transfusions from disease survivors might
offer a valuable anti-EBOV option in resource-limited settings
(459). Therapeutic strategies using chemical agents (e.g., neplano-
cin A, BCX4430, and lectins) against Ebola virus infections have
been reviewed elsewhere (337, 460). As for the treatment of
MARV infections, no drug or vaccine has been licensed, but sup-
portive therapies are regularly applied in clinical practice (327). A
recent study suggests that AVI-7288, which is a phosphorodiami-
date morpholino oligomer, potentially acts as postexposure pro-
phylaxis for MARV infections in humans (461). The efficacy of
antiviral candidates (e.g., ribavirin, PMO-Plus, and monoclonal
antibodies) against MARV has yet to be fully proven in clinical
trials (327).
Hendra and Nipah viruses from the family Paramyxoviridae
were first identified in 1994 and 1999, respectively. In Australia,
Equivac HeV has been approved as a Hendra virus vaccine in
horses (328). However, human vaccine development is hindered
by limited commercial benefits, because only 7 human Hendra
virus infections have been reported since 1994 (462). As for Nipah
virus infections, vaccine candidates (e.g., Hendra virus soluble G
glycoprotein subunit vaccine [HeV-sG]) are currently being in-
vestigated at a preclinical stage (463). Based on in vitro experi-
ments, ribavirin can efficiently inhibit henipavirus replication
(328). Moreover, preliminary clinical observations suggest that
ribavirin may inhibit human Hendra and Nipah virus infections,
despite controversial results being reported in different studies
(328). Although more clinical evidence is still needed, ribavirin
might be used as an off-label treatment for henipavirus infections
in the absence of other therapies (328).
Junin, Lassa, and Machupo viruses are human arenaviruses
from the family Arenaviridae. It has been shown that favipiravir
can efficiently inhibit viral replication of arenaviruses (Junin, Ma-
chupo, and Pichinde viruses) (338, 339). For vaccine develop-
ment, human HLA class I-restricted epitopes have been explored
for human arenaviruses (430). A number of Lassa and Junin virus
vaccine candidates (e.g., Candid#1, ML-29, and Tacaribe virus
[TACV] vaccine) have been tested in human or animal trials
(430). However, vaccine development for Lassa virus and filovi-
ruses is hindered by a lack of commercial interest (464).
Overall, for the control of infectious diseases, both vaccination
and antiviral drugs could be envisaged, but the availability of an-
tiviral treatments varies from one virus to another. As of April
2016, 22 infectious diseases are currently treated by licensed vac-
cines and/or antiviral drugs, but a broad spectrum of emerging
viruses is still at large. It is known that viruses from the same
family usually share similar features (465), and many emerging
viruses come from such virus families that possess at least one
virus targeted by vaccines and/or antiviral drugs. Therefore, FDA-
approved treatments might be active against emerging infectious
diseases in some circumstances.
CONCLUSIONS AND FUTURE PERSPECTIVES
To our knowledge, this article presents for the first time a com-
prehensive overview of 90 antiviral drugs approved over the past
50 years (Fig. 1). These antiviral drugs approved for the treatment
of 9 human infectious diseases have saved tens of millions of hu-
man beings over 5 decades, and they will continue to be essential
for antiviral treatments against current and emerging viral infec-
tions (Fig. 2). As of April 2016, various antiviral drugs offer prom-
ising activities against HCV infections, but a definitive cure for
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HIV, HBV, HCMV, HPV, HSV, RSV, VZV, or influenza virus is
yet to be discovered. In addition to approved antiviral drugs, our
review also highlights several forthcoming antiviral regimens in
phase 3 clinical trials (Table 3), because promising inhibitors (e.g.,
marine natural products [394]) have continuously been devel-
oped to fight against current and emerging infectious diseases.
During the past 5 decades, great achievements have been made
in the field of antiviral drug discovery. As of April 2016, many
antiviral drugs and/or vaccines have been approved for the treat-
ment of 22 infectious diseases: HIV, HBV, HCV, HCMV, HPV,
HSV, RSV, VZV, influenza virus, smallpox, rotavirus, human ad-
enovirus, human herpesvirus 6, poliovirus, hepatitis A virus, hep-
atitis E virus, Japanese encephalitis virus, yellow fever, rubella,
measles, mumps, and rabies (Table 4). Nevertheless, there is still
no antiviral drug or vaccine for more than 200 infectious diseases
that are afflicting human populations worldwide. In order to
highlight the latest progress in antiviral drug discovery, our review
provides a brief summary of potential antiviral agents and vac-
cines against 41 infectious diseases. It is our belief that new anti-
viral treatments will be formally approved to cure a broad range of
emerging infectious diseases in the future.
Importantly, antiviral compounds with broad-spectrum activ-
ity against different virus genotypes or subtypes are still welcome,
because the effectiveness of most antiviral drugs is limited to only
certain viral strains (466). For instance, some antiviral drugs (e.g.,
amprenavir) inhibit only HIV-1 but not HIV-2 (173). Many HCV
inhibitors have been approved only for HCV genotype 1 but not
for other genotypes (Table 2). Nevertheless, a number of antiviral
inhibitors (brivudine, acyclovir, TDF, foscarnet, famciclovir,
lamivudine, ribavirin, valacyclovir, PegIFN-2a, and PegIFN-
2b) have been licensed for the treatment of more than one virus
(Table 2), supporting the idea of developing antiviral drugs
against multiple infectious diseases in the future.
Despite the rapid advancement of pharmaceutical and bio-
technological approaches (e.g., RNA interference [RNAi] [467]),
the development of successful antiviral treatments remains a chal-
lenge. First, potent antiviral drugs that counteract the highly vari-
able nature of virus genomes are still required, because emerging
TABLE 4 Control of viral infections using approved vaccines and/or antiviral drugs
Group Family Virus(es) Vaccine Antiviral drug
I (dsDNA) Adenoviridae Human adenovirus Yes Off-label druga
Hepadnaviridae HBV Yes Yes
Herpesviridae VZV (shingles) Yes Yes
HSV, HCMV No Yes
EBV No No
Human herpesvirus 6 No Off-label druga
Papillomaviridae HPV Yes Yesb
Polyomaviridae Human polyomavirus No Off-label druga
Poxviridae Variola virus (smallpox) Yes Off-label druga
II (ssDNA) Parvoviridae Human parvovirus No No
III (dsRNA) Reoviridae Rotavirus Yes No
IV [()ssRNA] Astroviridae Human astrovirus No No
Caliciviridae Human sapovirus No No
Coronaviridae Human coronavirus No No
Flaviviridae HCV No Yes
Yellow fever virus Yes No
Japanese encephalitis virus Yes No
Dengue, West Nile, Zika viruses No No
Hepeviridae Hepatitis E virus Yesc No
Picornaviridae Hepatitis A virus, poliovirus Yes No
Norovirus, rhinovirus No No
Togaviridae Rubella virus Yes No
Chikungunya virus No No
V [()ssRNA] Arenaviridae Lassa, Junin, Machupo viruses No No
Filoviridae Ebola, Marburg viruses No No
Orthomyxoviridae Influenza virus Yes Yes
Paramyxoviridae RSV No Yes
Measles, mumps Yes No
Hendra, Nipah viruses No Off-label druga
Rhabdoviridae Rabies Yes No
VI [()ssRNA] Retroviridae HIV No Yes
a Cidofovir might be an off-label prescription to treat human polyomavirus, adenovirus, and smallpox. Foscarnet, ganciclovir, and cidofovir might be off-label drugs for HHV-6.
Ribavirin might be an off-label prescription for Hendra and Nipah virus infections.
b Three FDA-approved drugs (sinecatechins, podofilox, and imiquimod) are available for the treatment of external genital warts caused by HPV (354). However, these drugs may
not target HPV proteins directly.
c The HEV vaccine HEV239 was approved in China in 2012.
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drug resistance mutations remain a major cause of treatment fail-
ure (10, 466, 468, 469). Second, it is difficult to eradicate viral
reservoirs using antiviral agents, because DNA viruses and retro-
viruses can integrate their genomes into human genomes (470,
471). Third, it remains a challenge to rapidly develop antiviral
drugs and vaccines against emerging infectious diseases, calling
for a joint effort between scientific and industrial partners. Fourth,
it is a challenge to pursue effective, low-toxicity, and well-toler-
ated drugs that enhance patient compliance and drug administra-
tion (472). Fifth, efficient antiviral treatments against viral coin-
fections (e.g., HIV/HBV coinfections [473]) require further
investigations. Sixth, access to and delivery of costly new therapies
are becoming increasingly problematic in resource-limited set-
tings (474). Political and financial commitment is also vital to
eliminate substandard and counterfeit antiviral drugs that
threaten global public health (475).
Encouraged by the accelerated pace of drug discovery in the
past 5 decades, we anticipate that novel antiviral therapeutics will
ultimately contribute to elimination and eradication strategies
against human infectious diseases in the future.
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